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Abstract		
	
Despite	the	known	importance	of	zinc	for	human	immunity,	molecular	insights	into	its	roles	
have	remained	limited.	Here	we	report	a	novel	autosomal	recessive	disease	characterized	
by	absent	B	cells,	agammaglobulinemia	and	early-onset	infections	in	five	unrelated	families.	
The	immunodeficiency	results	from	hypomorphic	mutations	of	SLC39A7,	which	encodes	the	
endoplasmic	reticulum–to–cytoplasm	zinc	transporter	ZIP7.	Using	CRISPR-Cas9	mutagenesis	
we	have	precisely	modelled	ZIP7	deficiency	in	mice.	Homozygosity	for	a	null	allele	caused	
embryonic	death,	but	hypomorphic	alleles	reproduced	the	block	in	B	cell	development	seen	
in	patients.	B	cells	from	mutant	mice	exhibited	a	diminished	concentration	of	cytoplasmic	
free	zinc,	increased	phosphatase	activity	and	decreased	phosphorylation	of	signalling	
molecules	downstream	of	the	pre-B	cell	and	B	cell	receptors.	Our	findings	highlight	a	
specific	role	for	cytosolic	Zn2+	in	modulating	B	cell	receptor	signal	strength	and	positive	
selection.		
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The	molecular	dissection	of	primary	immunodeficiencies	is	a	powerful	means	of	elucidating	
genes	and	pathways	critical	for	immune	function.	In	the	case	of	B	cell	development,	linkage	
analysis	and	subtractive	hybridization	in	boys	with	X-linked	agammaglobulinemia	(XLA)	 led	
to	the	discovery	of	the	first	B	cell	immunodeficiency	disease	gene,	Bruton’s	Tyrosine	Kinase	
(BTK)1,	 2.	 This	 kinase	 is	 now	 the	 target	 of	 drugs	 effective	 in	 treating	 numerous	 B	 cell	
malignancies3.	 	Although	 its	expression	 is	not	confined	to	the	B	cell	 lineage,	 it	 is	 in	B	cells	
that	BTK	performs	its	major	non-redundant	function	as	a	signalling	molecule	downstream	of	
the	nascent	pre-B	and	B	cell	receptors	(BCR).			
	
B	 cells	must	 rearrange	 first	heavy	and	 then	 light	 chain	 immunoglobulin	 (Ig)	 genes	as	 they	
proceed	 through	 an	 orderly	 programme	 of	 development,	 and	 pass	 corresponding	 quality	
control	 checkpoints	 that	 signal	 the	 expression	 of	 first	 the	 pre-BCR	 and	 then	 the	 BCR	
respectively.	 Confirming	 the	 importance	 for	 developing	 human	 B	 cells	 of	 survival	 signals	
emanating	from	the	pre-BCR/BCR,	autosomal	recessive	causes	of	B	cell	deficiency	have	been	
identified	within	 the	 antigen	 receptor	 itself	 (IGHM,	 IGLL1),	 its	 signalling	 adaptors	 (CD79A,	
CD79B)	and	other	downstream	signal	transducers	(BLNK,	PIK3R1).	Together	with	BTK,	these	
defects	 of	 pre-BCR	 and	 BCR	 signalling	 account	 for	 the	 vast	 majority	 of	 early	 onset	
agammaglobulinemias,	and	 few	patients	 remain	without	a	molecular	diagnosis	 in	 the	USA	
and	Europe4-6.		
	
The	divalent	 cations,	 Ca2+	 and	Mg2+,	 are	well	 established	 as	mediators	 of	 lymphocyte	 cell	
signalling	 and	 inherited	 deficiency	 in	 their	 transmembrane	 transporters	 (ORAI17	 and	
MAGT18)	 causes	 a	 combined	 B	 and	 T	 cell	 immunodeficiency	 and	 a	 T	 or	 NK	 cell	
immunodeficiency	 respectively.	 A	 third	 divalent	 cation,	 Zn2+,	 contributes	 to	 the	 structural	
and	functional	integrity	of	over	3,000	proteins,	and	is	tightly	regulated	by	buffering	and	by	
14	SLC39A	(ZIP)	and	10	SLC30A	(ZnT)	Zn2+	transporters,	which	control	the	movement	of	Zn2+	
between	 the	 cytosol	 and	 the	 extracellular	 space	 or	 cytoplasmic	 organelles9.	 Dietary	 zinc	
deficiency	 causes	 lymphopenia10	 and	 loss	 of	 ZIP10	 has	 also	 been	 associated	 with	 B	 cell	
immunodeficiency	 in	 mice11;	 however,	 the	 mechanism(s)	 by	 which	 Zn2+	 might	 regulate	
lymphocyte	 development	 in	 humans	 are	 not	 established.	 	 The	 MHC	 region	 of	 human	
chromosome	 6,	 which	 is	 highly	 enriched	 for	 immunologically	 relevant	 genes,	 includes	 a	
single	Zn2+	transporter,	originally	termed	“Really	Interesting	New	Gene	5”	or	HKE4	but	now	
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known	as	SLC39A7.	 	No	immunological	function	has	previously	been	ascribed	to	this	gene.	
Here	 we	 report	 a	 novel	 human	 immunodeficiency	 syndrome	 caused	 by	 multiple	 loss	 of	
function	 alleles	 in	 SLC39A7	 (ZIP7),	 which	 lead	 to	 reduced	 B	 cell	 signalling	 at	 the	 positive	
selection	checkpoints.	
	
	
Results	
	
A	novel	human	immunodeficiency	syndrome	
We	 used	 whole	 exome	 sequencing	 to	 investigate	 patients	 with	 early	 onset	
agammaglobulinemia	 and	 absent	 B	 cells	 of	 unknown	 cause,	 and	 sought	 candidate	
autosomal	 recessive	 disease	 genes	 bearing	 rare	 biallelic	 variants.	 	 Six	 individuals	 from	 5	
kindreds	 of	 white	 European,	 South	 Asian	 or	 Hispanic	 ancestry,	 were	 found	 to	 harbor	
compound	heterozygous	(4	families)	or	homozygous	(1	family)	rare	variants	in	SLC39A7	(Fig.	
1a).	This	gene,	not	previously	linked	to	the	immune	system	other	than	by	its	location	within	
the	 MHC	 complex	 on	 chromosome	 6,	 encodes	 ZIP7,	 a	 ubiquitously	 expressed	 channel	
protein	that	regulates	Zn2+	egress	from	the	endoplasmic	reticulum	(ER)	into	the	cytoplasm12.	
Consistent	 with	 a	 causal	 link	 to	 a	 rare	 autosomal	 recessive	 disease,	 population	 data13	
revealed	 that	 none	 of	 the	 patients’	 variants	 of	 SLC39A7,	 nor	 any	 predicted	 null	
(nonsense/frameshift/essential	 splice-site)	alleles,	occurs	with	a	 frequency	of	greater	 than	
1/1,000	(Supplementary	Fig.	1)	and	none	has	previously	been	found	in	a	homozygous	state.	
In	general,	patients’	 ethnicity	matched	 that	of	 the	population	 in	which	 the	 corresponding	
SLC39A7	 variant(s)	 had	 been	 reported;	 two	 missense	 alleles	 each	 occurred	 in	 two	
independent	kindreds	of	European	ancestry.	The	five	missense	and	two	nonsense	variants	
were	all	predicted	to	be	deleterious	(CADD	score	≥25)14	(Supplementary	Fig.	1).		
	
Affected	 individuals	 presented	 with	 early	 onset	 infections,	 agammaglobulinemia	 and	
absence	of	circulating	B	cells	but	normal	T	cell	numbers	and	proliferative	responses	(Table	1	
and	 Supplementary	 Table	 1).	 Naïve	 T	 cells	 were	 abundant,	 in	 keeping	 with	 age,	 while	
effector	and	memory	subsets	were	correspondingly	reduced	but	not	absent.	The	two	most	
severely	 affected	 children	 (P1	 and	 P2,	 family	 1)	 additionally	 showed	 severe	 blistering	
dermatosis	(Fig.	1b),	failure	to	thrive	and	thrombocytopenia,	prompting	hematopoietic	stem	
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cell	transplantation;	this	resulted	in	cure	of	immunologic	abnormalities	and	amelioration	of	
skin	disease.		Other	patients	have	generally	responded	well	to	Ig	replacement	therapy	alone,	
although	 P4	 has	 suboptimal	 growth,	 enteropathy	 and	 liver	 dysfunction	 while	 P5	 has	
seborrheic	dermatitis.	Family	members	who	were	heterozygous	for	a	wild	type	(WT)	and	a	
mutant	allele	demonstrated	normal	immune	function.	Bone	marrow	(BM)	examination	in	P1	
and	 P2	 showed	 a	 progressive	 failure	 of	 B	 cell	 development	with	 an	 excess	 of	 pro-B	 cells	
relative	to	pre-B	cells,	and	an	even	 lower	proportion	of	 immature	B	cells	 relative	to	pre-B	
cells,	similar	to	that	seen	in	XLA	caused	by	mutations	in	BTK	(Fig.	1c)4.		
	
To	 explore	 the	 impact	 of	 disease-associated	 mutations,	 we	 first	 examined	 ZIP7	 protein	
expression	 by	 immunoblotting	 and	 immunofluorescence	 microscopy	 in	 primary	 patient	
fibroblasts	(Fig.	2a	and	Supplementary	Fig.	2a),	and	transfected	cell	lines	(Fig.	2b-e).	Similar	
to	endogenous	WT	ZIP7	(Fig.	2c),	each	variant	was	expressed	and	predominantly	localized	to	
the	ER	of	transfected	cells	(Fig.	2d,	e),	although	the	protein	products	of	nonsense	variants	
were	truncated	when	visualized	on	SDS-PAGE	(Fig.	2b).		The	detrimental	effects	of	missense	
amino	 acid	 substitutions	 were	 illuminated	 by	 modelling	 into	 the	 predicted	 multi-pass	
membrane	 channel	 structure	 of	 human	 ZIP7,	 based	 on	 alignment	 with	 a	 recently	 solved	
bacterial	ZIP	(BpZIP;	26%	sequence	identity)(Fig.	2f,	g	and	Supplementary	Fig	1c)15.	In	most	
cases,	 the	 amino	 acid	 change	 (P190A,	 L217P,	G458A)	 involves	 either	 a	 glycine	 or	 proline,	
residues	that	are	often	conserved	and	known	to	be	critical	for	membrane	protein	structure.	
In	the	case	of	P190A	and	L217P,	the	removal	and	introduction	of	a	proline,	respectively,	is	
likely	 to	affect	 the	conformation	and/or	dynamics	of	 their	 respective	helices,	and	perhaps	
that	 of	 the	 intervening,	 histidine-rich	 cytoplasmic	 loop.	 The	 G458A	 change	 will	 disrupt	
packing	interactions	of	helices	H8	and	H2	in	the	protein	 interior,	which,	with	H2	lining	the	
active	site,	is	likely	to	disrupt	function.	Of	the	remaining	two	mutations,	T395I	is	at	first	sight	
enigmatic,	because	it	corresponds	to	a	semi-conservative	change	of	a	lipid-exposed	residue.	
However,	 this	most	 likely	reflects	an	alignment	gap;	once	both	H6	helices	are	aligned,	the	
Thr395	 corresponds	 to	 Glu240	 in	 BpZIP	 (or	 an	 adjacent	 residue),	 one	 of	 the	 active	 site	
residues	coordinating	Zn2+	within	the	channel.	The	effect	of	the	final	E363K	mutation	is	very	
clear,	as	this	will	place	a	positively	charged	side	chain	in	or	near	this	active	site	(Fig.	2f	and	g).	
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These	analyses	 strongly	 implied	 that	disease	alleles	were	either	null	or	hypomorphic	with	
respect	 to	 Zn2+	 transport	 function.	 To	 test	 this	 hypothesis,	 we	 compared	 the	 function	 of	
P190A	and	E363K	missense	mutants,	which	were	co-expressed	in	the	most	severely	affected	
family	1,	with	WT	ZIP7,	by	injecting	mRNA	transcripts	into	Xenopus	oocytes	and	visualizing	
Zn2+	 ingress	 by	 means	 of	 a	 Zn2+-sensitive	 dye	 (Fig.	 2h	 and	 Supplementary	 Fig.	 2b,	 c).	 In	
keeping	with	hypomorphic	behavior,	 the	Zn2+	 signal	generated	by	either	mutant	ZIP7	was	
significantly	 reduced	 compared	 with	 WT	 (Fig.	 2h),	 despite	 similar	 amounts	 of	 protein	
expression	 (Supplementary	 Fig.	 2c).	 Similar	 data	 were	 obtained	 in	 mammalian	 cells	
transfected	 with	 a	 eCALWY-4	 Fluorescence	 Energy	 Transfer	 (FRET)	 probe	 for	 cytoplasmic	
Zn2+	alongside	WT	or	mutant	ZIP7	 (Supplementary	Fig.	2d	and	e)16.	Taken	 together,	 these	
studies	 imply	 residual	 ZIP7	 protein	 expression	 but	 reduced	 function	 in	 patients	 bearing	
pathogenic	mutations.	
	
Mouse	ZIP7	hypomorphs	model	human	disease		
To	model	the	human	disease,	we	used	CRISPR-Cas9	genome	editing17	to	generate	C56BL/6J	
(B6)	 mice	 carrying	 a	 ZIP7	 P198A	 mutation,	 orthologous	 to	 the	 most	 N	 terminal	 human	
P190A	mutation	found	in	2	independent	kindreds.	We	chose	a	knock-in	rather	than	a	knock-
out	approach	because	we	suspected	complete	loss	of	function	would	be	embryonic	lethal.	
The	 error-prone	 non-homologous	 end-joining	 repair	 pathway	 nonetheless	 generated	 a	
series	of	different	ZIP7	alleles	in	mouse	zygotes,	which	allowed	us	to	investigate	a	range	of	
phenotypes.	 These	 variants	 included	 null	 alleles	 due	 to	 frameshift	 mutations,	 the	 P198A	
mutation	itself,	and	an	insertional	mutant	H199QV,	which	was	also	expressed	at	the	protein	
level	(Fig.	3a).	
	
Mice	 with	 homozygous	 (ZIP7P198A/P198A	 or	 ZIP7H199QV/H199QV)	 or	 compound	 heterozygous	
(ZIP7P198A/H199QV)	hypomorphic	mutations	demonstrated	profound	B	 cell	 immunodeficiency	
(Fig.	 3b),	 whereas	 heterozygous	 mice	 with	 wild-type	 alleles	 had	 normal	 B	 cell	 numbers.	
Other	 effects	 of	 the	 ZIP7	 mutations	 on	 growth	 and	 skin	 varied	 by	 allele,	 with	 severity	
ranging	 from	WT	<	H199QV	<	 P198A	<	 null.	Homozygous	 ZIP7H199QV/H199QV	 and	 compound	
heterozygous	 ZIP7P198A/H199QV	 mice	 showed	 mild	 weight	 restriction	 compared	 with	 WT,	
whereas	ZIP7P198A/P198A	mice	were	growth	retarded	with	mottled	gray	fur,	and	few	of	these	
animals	 survived	 beyond	 6	 weeks	 (Fig.	 3c	 and	 d).	 ZIP7-/-,	 ZIP7-/P198A	 and	 ZIP7-/H199QV	mice	
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carrying	the	null	allele	could	not	be	obtained.	These	findings	are	consistent	with	an	absolute	
requirement	 for	 some	 residual	 ZIP7	 function	 during	 embryonic	 development,	 albeit	 less	
than	 that	 required	 for	 developing	 B	 cells.	 	 The	murine	 ZIP7	mutations	 therefore	 lead	 to	
quantitative	 traits	 affecting	 the	 skin	 and	 growth,	 and	 a	 qualitative	 trait	 affecting	 B	 cell	
development	(Fig	3e).	
	
To	investigate	the	role	of	ZIP7	in	B	cell	development,	we	focused	on	mice	homozygous	for	
the	hypomorphic	P198A	allele,	mimicking	one	of	the	human	disease	variants.	 	Comparison	
of	25-day-old	WT	and	ZIP7P198A/P198A	mice	showed	strikingly	reduced	numbers	of	B220+CD43-
IgM-IgD-	 late	pre-B	cells	 (Hardy	fraction	(Fr)	D),	B220+CD43-IgM+IgD-	 immature	B	cells	 (FrE)	
and	recirculating	B220+CD43-IgM+IgD+	mature	B	cells	(FrF)	in	the	ZIP7-deficient	BM	(Fig.	4a	
and	b)18.	Peripheral	B	cell	numbers	were	further	reduced	in	the	spleen	with	progressive	loss	
from	 CD93+IgMhiCD23-	 transitional	 T1	 to	 CD93+IgMhiCD23+	 T2,	 CD93+IgM+CD23+	 T3,	 CD93-
IgM+IgD+CD23+CD21+	follicular	and	CD93-IgMhiIgD-CD23-CD21hi	marginal	zone	B	cells	(Fig.	4a	
and	b).	 	 To	 compare	absolute	numbers	of	developing	B	 cell	 subsets	 independently	of	 the	
small	size	of	ZIP7P198A/P198A	mice,	we	reconstituted	lethally	irradiated	CD45.1+	WT	mice	for	8	
weeks	with	WT	or	ZIP7P198A/P198A	CD45.2+	BM	and	repeated	our	analysis.	 	This	confirmed	a	
highly	significant	reduction	in	developing	B	cell	numbers,	which	was	most	evident	in	Hardy	
FrD	and	FrE	 (Fig	4c).	There	was	no	 rescue	of	B	cell	development	 in	BM	chimeric	mice	 fed	
0.5mM	 ZnSO4.7H20	 in	 drinking	water	 for	 the	 8	weeks	 period	 of	 reconstitution:	 0.73	 x106	
(95%	CI	0.71-0.74	x	106,	n=4)	and	0.79	x	106	(0.76-0.81	x	106,	n=4)	splenic	follicular	B	cells	
respectively	in	untreated	and	treated	ZIP7P198A/P198A	mice,	compared	to	85.9	x	106	(85.6-86.1	
x	106,	n=5)	and	85.4	x	106	(85.03-85.9	x	106,	n=5)	respectively	in	WT	mice.	
	
B	cells	constituted	only	0.76%	(0.76-0.77%,	95%	CI)	of	 total	blood	 lymphocytes	 in	4-week-
old	 ZIP7P198A/P198A	mice,	 compared	 to	 27.96%	 (27.71-28.21%,	 95%	 CI)	 in	 age-matched	WT	
controls;	 and	 serum	 IgM	antibody	concentrations	 in	4-6	week	ZIP7P198A/P198A	and	WT	mice	
were	 104	 µg/ml	 (103-106	 µg/ml,	 95%	 CI)	 and	 383	 µg/ml	 	 (378-388	 µg/ml,	 95%	 CI)	
respectively.	 Because	 ZIP7P198A/P198A	mice	 rarely	 survived	 long	 after	 weaning,	 endogenous	
IgG	production	could	not	be	assessed.		However,	mice	of	the	milder	hypomorphic	genotype	
ZIP7P198A/H199QV	showed	a	dramatic	decline	 in	 IgG	concentrations	beyond	this	age	(146-150	
µg/ml,	95%	CI,	compared	to	1830-1870	µg/ml,	95%	CI,	in	WT	mice,	aged	7-13	weeks).		T	cell	
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development	 and	 peripheral	 T	 cell	 numbers	 were	 normal,	 as	 were	 other	 leukocyte	
populations	 (Supplementary	 Fig.	 3).	 These	 data	 thus	 confirmed	 a	 selective	 and	 profound	
failure	of	B	cell	development	in	ZIP7-mutated	mice.	
	
Developmental	arrest	in	ZIP7-deficient	B	cells	
To	distinguish	between	cell-intrinsic	and	 -extrinsic	effects	on	B	cell	development,	we	next	
generated	mixed	BM	 chimeras.	 30:70	mixes	 of	 CD45.1+	WT	 and	CD45.2+	 ZIP7P198A/P198A	 or	
CD45.2+	WT	whole	BM	cells	were	injected	intravenously	into	lethally	irradiated	CD45.1+	WT	
recipient	mice.		Eight	weeks	after	BM	transfer,	our	analysis	confirmed	a	B	cell	intrinsic	block	
in	development,	which	was	most	evident	in	a	failure	to	progress	from	the	late	pre-B	(FrD)	to	
immature	B	(FrE)	cell	stage,	with	no	residual	mutant	cells	in	the	recirculating	FrF	population	
(Fig.	 4d).	 This	 developmental	 block	 was	 mirrored	 in	 the	 spleen	 with	 progressive	 loss	 of	
transitional	B	 cells	 from	T1	 to	T3	 (Fig.	 4d);	whereas	ZIP7-mutated	CD4+	and	CD8+	T	 cells	in	
thymus	and	spleen	were	not	disadvantaged	relative	to	WT	cells	(Supplementary	Fig.	3).		We	
cannot	exclude	a	cell-intrinsic	effect	during	the	early	pre-B	cell	stage	(FrC),	which	might	have	
been	masked	due	to	the	small	numbers	of	cells	and	difficulty	of	gating	on	CD45	allotypes	at	
this	stage.	Mutant	and	WT	immature	B	cells	expressed	kappa	and	lambda	chains	in	similar	
ratios	(90%	kappa	and	5%	lambda	in	mutant	compared	to	95%	and	5%	in	WT),	excluding	a	
defect	in	the	light	chain	rearrangement	machinery.	
	
To	gain	a	better	understanding	of	the	impact	of	ZIP7	hypofunction	on	B	cell	development,	
we	flow-sorted	100-cell	aliquots	of	each	of	the	Hardy	fractions	from	ZIP7P198A/P198A	and	WT	
mice	 for	RNA-seq,	 and	were	able	 to	obtain	 good	quality	RNA	 from	B220+CD43+CD24+BP1-	
pro-B	(FrB),	 late	pre-B	(FrD)	and	 immature	B	cells	 (FrE)	 (Fig.	5a	and	Supplementary	Figs.	4	
and	 5).	 	 Focusing	 on	 transcripts	 that	 are	modulated	 during	mouse	 B	 cell	 development	 in	
ImmGen	 (www.immGen.org),	 we	 observed	 a	 systematically	 altered	 pattern	 of	 gene	
transcription	consistent	with	developmental	delay	 in	ZIP7-deficient	pre-B	and	 immature	B	
cells,	 but	 not	 at	 the	 earlier	 pro-B	 stage.	 	 Thus,	 the	 few	 ZIP7-deficient	 cells	 bearing	 the	
surface	markers	of	FrE	had	in	fact	failed	to	exit	fully	from	the	transcriptional	profile	of	FrD	
and,	 likewise,	 ZIP7-deficient	 cells	 in	 FrD	 abundantly	 expressed	 transcripts	 normally	
associated	with	 FrC	 (Fig.	 5a	 and	 Supplementary	 Fig.	 5).	 	 In	 contrast,	 few	 transcripts	were	
differentially	 expressed	 between	 WT	 and	 ZIP7-deficient	 FrB	 and	 these	 did	 not	 follow	 a	
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pattern	 of	 developmentally	 coordinated	 gene	 expression	 (Supplementary	 Fig.	 4).	 The	
analysis	 showed	 no	 statistically	 significant	 difference	 in	 expression	 of	 other	 ZIP	 and	 ZnT	
transporters	in	Fr	D	and	E	(see	materials	and	methods).	
	
ZIP7-deficient	 immature	 B	 cells	 continued	 to	 express	 Rag	 and	 Il7r	 genes,	 and	 failed	 to	
upregulate	characteristic	FrE	transcripts	such	as	Tnfrsf13c	 (BAFFR)	and	Ms4a1	 (CD20)	 (Fig.	
5a).		This	indicates	a	failure	of	the	normal	transition	from	late	pre-B	to	immature	B	cells,	at	
which	 stage	 constitutive	 BCR	 signalling	 would	 normally	 repress	 FOXO1-dependent	 genes	
involved	 in	 light	 chain	 gene	 rearrangement	 (Rag1/2	 and	 Irf4)	 and	 cell	 proliferation	 (Il7r),	
followed	 by	 upregulation	 of	 proteins	 including	 BAFFR	 that	 mediate	 peripheral	 survival	
signals19,	 20.	 These	 key	 findings	 were	 confirmed	 at	 the	 protein	 level	 by	 flow	 cytometry,	
including	 the	 failure	 to	 downregulate	 IL7Ra	 (CD127;	 Fig.	 5b)	 and	 upregulate	 BAFFR	 and	
CD20	(Fig.	5c).	The	same	developmental	blockade	was	observed	in	BM	samples	from	both	
patients	that	were	compound	heterozygous	for	the	P190A	and	E363K	variants	(Fig.	5d).	Thus,	
in	 contrast	 to	 BTK	 deficiency,	 ZIP7	 mutation	 subverts	 both	 mouse	 and	 human	 B	 cell	
development	in	a	profound	and	conserved	manner.	
	
Reduced	cytoplasmic	Zn2+	
Given	 that	 ZIP7	 allows	 the	 cytoplasmic	 ingress	 of	 Zn2+	 from	 the	 ER,	we	 reasoned	 that	 its	
impaired	function	would	alter	Zn2+	distribution	in	developing	B	cells,	reducing	its	availability	
in	the	cytoplasm.	To	provide	sufficient	material	to	investigate	this	hypothesis,	we	generated	
B	cell	lines	from	WT	and	P198A	homozygous	mutant	mouse	BM	maintained	in	IL-7-	enriched	
media.		WT	and	mutant	cells	cultured	in	these	conditions	showed	comparable	proliferation	
and	differentiation	 to	a	predominantly	CD43+CD24+BP-1+/-	phenotype,	which	 is	considered	
equivalent	 to	 Fractions	 B-C-C’	 in	 B	 cell	 development21,	 22.	 The	 withdrawal	 of	 IL-7	 and	
addition	of	BAFF	to	these	cultures	increased	the	survival	of	IgM+IgD-	immature	and	IgM+IgD+	
mature	B	cells	 from	WT	but	not	from	mutant	cells	 (Fig	6a).	 In	this	way,	the	model	system	
recapitulated	the	developmental	block	seen	in	vivo.		
	
To	measure	 the	 cytoplasmic	 and	 ER	 concentrations	 of	 Zn2+	 at	 the	 point	 of	 blockade,	 we	
transduced	 aliquots	 of	 IL-7-cultured	 cells	 with	 either	 the	 cytoplasmic	 or	 the	 ER-targeted	
versions	of	Zn2+	FRET	reporters,	eCALWY-4	 (Kd	630	pM)	or	eCALWY-6	 (Kd	2.9	nM)16,	23.	We	
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then	measured	the	relative	cytoplasmic	and	ER	concentrations	of	Zn2+	in	propidium	iodide-
negative	WT	and	mutant	cells	(>95%)	using	FRET-fluorescence	lifetime	imaging	microscopy	
(FRET-FLIM)24.	An	advantage	of	this	approach	is	that	lifetime	imaging	is	independent	of	the	
concentration	 of	 measured	 fluorophore,	 and	 hence	 free	 Zn2+	 concentrations	 can	 be	
compared	 independently	 of	 reporter	 expression24.	 Cytoplasmic	 Zn2+	 concentrations	 were	
indeed	 lower	 in	mutant	compared	to	WT	cells,	whereas	ER	Zn2+	amounts	were	equivalent	
(Fig.	6b	and	c).		
	
In	 this	system,	the	spatial	distribution	of	cytoplasmic	Zn2+	appeared	uniform	 in	the	steady	
state	 in	 both	 WT	 and	 mutant	 B	 cells	 (Fig.	 6b).	 	 However,	 local	 variations	 in	 Zn2+	
concentration	 would	 most	 likely	 be	 beyond	 the	 temporal	 and	 spatial	 resolutions	 of	 the	
current	 FRET-FLIM	 approach.	 	 It	 was	 therefore	 of	 interest	 to	 investigate	 the	 spatial	
distribution	of	endogenous	ZIP7	in	the	relevant	cell	type,	taking	advantage	of	a	sensitive	and	
specific	anti-human-ZIP7	antibody.		Using	stimulated	emission	depletion	(STED)	microscopy,	
we	observed	that	>50%	ZIP7-containing	structures	lay	within	1µm	(and	25%	within	250nm)	
of	 the	 plasma	 membrane	 of	 activated	 human	 primary	 B	 cells,	 in	 contrast	 to	 the	 wider	
distribution	seen	in	the	cytoplasm	of	the	much	larger	HEK293T	cells	(Fig.	6d	-	f).		Thus	local	
and/or	dynamic	changes	in	Zn2+	distribution	related	to	ZIP7	might	differ	between	cell	types.	
	
Developmental	arrest	is	linked	to	a	survival	defect	
In	principle,	the	failure	of	ZIP-mutated	B	cells	to	complete	their	development	could	reflect	a	
lack	of	requisite	survival	signals	via	the	(pre-)BCR	and/or	accessory	pathways,	or	excessive	
toxicity.	Although	we	had	failed	to	observe	an	excess	of	free	Zn2+	 in	the	ER	of	B	cells	from	
the	 ZIP7P198A/P198A	 mice,	 we	 considered	 the	 possibility	 that	 zinc	 loading	 of	 the	 ER	 could	
nonetheless	drive	an	unfolded	protein	response	(UPR),	as	recently	described	in	the	gut	and	
skin	 of	 gene-targeted	mice	with	 tissue-specific	 ZIP7	 knockout25,	26.	 However,	 our	 RNA-seq	
data	 revealed	 no	 evidence	 of	 an	 UPR	 transcriptional	 signature	 in	 the	 mutant	 pre-B	 or	
immature	B	 cells,	nor	was	Xbp1	 splicing	altered	 (Supplementary	Fig.	6a).	 Therefore,	while	
the	UPR	may	underlie	some	of	the	extra-hematopoietic	effects	of	ZIP7	deficiency,	 it	 is	not	
limiting	in	B	cells.		
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We	next	asked	whether	expression	of	the	anti-apoptotic	survival	factor	B-cell	 lymphoma	2	
(BCL2)	 could	 rescue	 B	 cell	 development	 at	 the	 pre-B	 to	 immature	 stage	 in	 ZIP7P198A/P198A	
mice.	 Introduction	 of	 a	 B	 cell	 specific	Bcl2	 transgene	 (from	 C57BL/6-Tg(BCL2)22Wehi/J)27	
increased	peripheral	B	cell	numbers	in	both	WT	and	ZIP7P198A/P198A	mice	but	did	not	relieve	
the	developmental	block	(Supplementary	Fig.	6b-e).	This	suggested	that	ZIP7	deficiency	was	
not	 simply	 accelerating	 the	 death	 of	 otherwise	 normally	 developing	 B	 cells,	 but	 was	
fundamentally	 impairing	 the	 process	 of	 B	 cell	 differentiation,	 in	 keeping	 with	 the	
systematically	altered	program	of	gene	expression	detected	by	RNAseq.	
	
Intact	ZIP7	is	required	for	BCR	signalling	
Given	that	Ig	heavy	chain	expression	is	required	for	the	transition	from	pro-B	to	pre-B28	and	
Ig	 light	 chain	 expression	 for	 the	 pre-B	 to	 immature	 B	 cell	 transition29,	we	 considered	 the	
possibility	 that	 ZIP7	 deficiency	 impaired	 (pre-)BCR	 expression	 or	 signalling.	 To	 bypass	 the	
need	 for	 DNA	 recombination	 by	 RAG1/2	 at	 both	 pro-B	 and	 pre-B	 cell	 stages,	we	 crossed	
ZIP7P198A/P198A	mice	with	animals	expressing	a	 transgenic	anti-hen	egg	 lysozyme	(anti-HEL)-
specific	 BCR	 (SWHEL	mice)30.	 This	 generated	WT	 and	 ZIP7P198A/P198A	immature	 SWHEL	 B	 cells	
expressing	 equivalent	 levels	 of	 surface	 BCR	 (Fig.	 7a-c),	 enabling	 us	 to	 interrogate	 the	
integrity	of	 the	downstream	signalling	pathway.	 	Despite	normal	BCR	expression	 (Fig.	7c),	
ZIP7P198A/P198A	B	 cells	 still	 failed	 to	mature	normally,	as	 indicated	by	 lower	cell	numbers	 in	
the	spleen	(Fig.	7b)	and	an	inability	to	upregulate	CD20	and	BAFFR	(Fig.	7c).	Moreover,	when	
exposed	to	soluble	HEL	(sHEL)	antigen	or	to	anti-IgM,	immature	ZIP7P198A/P198A	SWHEL	B	cells	
showed	 impaired	 antigen-induced	 signalling	 as	 judged	 by	 reduced	 amounts	 of	 multiple	
phosphorylated	intermediates,	including	SYK,	PLCg2	and	ERK	(Fig.	7d	and	e).	This	effect	was	
specific	to	B	cells	because	signalling	was	unaffected	in	developing	T	cells	(Supplementary	Fig	
7).			
	
A	priori,	these	complex	effects	on	pathways	downstream	of	the	BCR	could	be	mediated	by	
variation	 in	 kinase	or	phosphatase	activity.	 Since	Zn2+	 is	widely	 reported	 to	be	a	negative	
regulator	 of	 phosphatases31,32,	 the	 diminished	 cytoplasmic	 Zn2+	 associated	 with	 ZIP7	
deficiency	 could	 be	 expected	 to	 cause	 pathologically	 elevated	 phosphatase	 activity,	 and	
thus	contribute	to	impaired	pre-BCR-	and	BCR-dependent	signalling	at	the	positive	selection	
check-points.	 Constitutive	 phosphatase	 activity	 was	 indeed	 higher	 in	 ZIP7P198A/P198A	
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compared	to	WT	pre-B	and	 immature	B	cells,	as	measured	by	flow	cytometry	using	a	cell-
permeable	 alkaline	 phosphatase	 substrate	 (Fig.	 8a	 and	 b).	 The	 phosphatase	 and	 tensin	
homolog	(PTEN)	is	among	the	phosphatases	previously	described	as	being	inhibited	by	Zn2+,	
lies	 upstream	of	 FOXO1-dependent	 signalling33,	 and	 contributes	 to	 the	basal	 phosphatase	
activity	measured	 in	 developing	 B	 cells	 (Supplementary	 Fig.	 8a).	 Progressive	 inhibition	 of	
PTEN	 with	 its	 specific	 inhibitor	 BpV(phen)	 also	 revealed	 lower	 amounts	 of	 constitutive	
signalling	to	SYK,	PLCg2	and	ERK	 in	 immature	ZIP7P198A/P198A	SWHEL	B	cells	compared	to	WT	
SWHEL	B	cells	(Fig.	8c),	but	not	in	developing	T	cells	(Supplementary	Fig	7d-f),	in	keeping	with	
constitutively	increased	phosphatase	and/or	lower	basal	kinase	activity	during	the	stage	of	B	
cell	positive	selection.	We	could	detect	no	variation	 in	kinase	gene	expression	 (equivalent	
transcription	of	SYK,	BLNK,	PLCg2	and	ERK	in	FrE	by	RNA-seq);	and	no	difference	in	protein	
expression	 of	 PLCg2,	 which	 we	 were	 able	 to	 detect	 reliably	 by	 flow	 cytometry	
(Supplementary	Fig.	8b).	However,	crossing	ZIP7P198A/P198A	mice	to	mice	with	B	cell	specific	
haploinsufficiency	 of	 PTEN	 could	 not	 reverse	 the	 block	 in	 B	 cell	 development	
(Supplementary	Fig.	8c	and	d).	These	data	indicate	that	the	regulation	of	positive	selection	
by	ZIP7	is	due	to	effects	on	multiple	pathways.	
	
Discussion	
	
Our	 studies	 identify	 a	 novel	 form	of	 autosomal	 recessive	 agammaglobulinemia	 caused	by	
hypomorphic	 mutations	 in	 the	 ER-to-cytoplasmic	 zinc	 transporter	 ZIP7.	 This	 discovery	
implicates	 Zn2+	 as	 the	 third	 divalent	 cation	 associated	 with	 a	 human	 immunodeficiency.	
Despite	 zinc’s	 status	as	 a	 key	player	 in	protein	 structure	and	 function,	we	are	at	 an	early	
stage	in	understanding	its	broader	roles	in	homeostasis	and	human	disease.	Its	tight	control	
by	buffering,	and	the	diversity	of	Zn2+	transporters,	indicate	that	dynamic	regulation	of	Zn2+	
distribution	 is	 critical.	 This	 conclusion	 is	 supported	 by	 knowledge	 that	 mutations	 in	 the	
human	plasma	membrane	Zn2+	transporter,	SLC39A4	(ZIP4),	cause	total	body	Zn	deficiency	
and	 a	 separate	 but	 related	 disease,	 acrodermatitis	 enteropathica34.	 As	 well	 as	 a	
pathognomonic	dermatitis	and	a	variable	enteropathy,	 it	 is	noteworthy	 that	Zn	deficiency	
causes	lymphopenia,	with	accelerated	apoptosis	of	developing	B	cells35.			
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Importantly,	the	SLC39A7	 (ZIP7)	disease	alleles	are	hypomorphic	and	exhibit	partial	 loss	of	
ZIP7	 function.	 It	 was	 recently	 reported	 that	 complete	 loss	 of	 ZIP7	 in	 cell	 lines	 causes	 a	
reduction	 in	 cytoplasmic	 Zn2+	 and	 an	 increase	 in	 ER	 Zn2+	 concentrations	 as	 quantified	 by	
mass	 spectrometry36;	 and	 our	 findings	 show	 that	 germline	 null	mutations	 are	 embryonic	
lethal	in	the	mouse.	Tissue-specific	ZIP7	knock-out	in	the	gut	of	mice	by	cre-mediated	gene	
deletion	 reduces	 intestinal	 epithelial	 cell	 self-renewal	 and	 is	 associated	with	 an	 ER	 stress	
phenotype25.	 ER	 stress	 is	 also	 caused	 by	 null	 mutations	 of	 catsup,	 the	 Drosophila	 ZIP7	
homologue37;	and	loss	of	Ke4,	which	is	the	ZIP7	homologue	in	zebrafish,	results	in	eye,	brain	
and	skeletal	malformations38.		We	postulate	that	residual	ZIP7	function	in	patients	protects	
these	tissues	from	the	effects	of	extreme	Zn2+	redistribution	including	ER	stress.		
	
Our	 findings	 emphasise	 the	 specific	 sensitivity	 of	 mammalian	 B	 cell	 development	 to	
perturbations	of	Zn2+	homeostasis.	 	Whereas	most	 tissues	 tolerate	partial	 ZIP7	deficiency,	
developing	B	cells	are	profoundly	affected	and	fail	to	progress	beyond	the	pre-B-cell	stage.	
Such	 developmental	 blockade	 is	 characteristic	 of	 over	 90%	 of	 primary	
agammaglobulinemias,	which	are	 typically	associated	with	 specific	 impairment	of	pre-BCR	
and/or	BCR	signalling4.	Our	data	suggest	that	ZIP7	hypofunction	likewise	impedes	signalling	
by	the	nascent	BCR	during	positive	selection,	and	that	this	may	be	in	part	due	to	defective	
Zn2+-dependent	 inhibition	 of	 phosphatase	 activity.	 In	 the	 chicken	 B	 cell	 line	 DT40,	 which	
does	 not	 possess	 a	 homologue	 of	 ZIP7,	 ZIP9-dependent	 Zn2+	 transport	 was	 similarly	
reported	 to	enhance	BCR	 signalling	by	negatively	 regulating	phosphatase	activity39.	 CD74-
cre	mediated	deletion	of	 ZIP10,	which	 transports	 Zn2+	 across	 the	plasma	membrane,	 also	
reduced	 mature	 B	 cell	 numbers	 and	 BCR-induced	 B	 cell	 proliferation	 in	 mice;	 yet,	
paradoxically,	 this	 was	 reportedly	 associated	 with	 increased	 BCR	 signalling	 and	 reduced	
CD45	activity11.		Unravelling	these	complex	effects	of	individual	transporters	will	require	the	
development	 of	 improved	 reporters	 to	 resolve	 changes	 in	 Zn2+	 levels	 dynamically	 and	 at	
higher	spatial	resolution.		
	
The	 selective	 sensitivity	 of	 developing	 B	 cells	 to	 deficiency	 of	 one	 among	 several	
ubiquitously	expressed	Zn2+	transporters	might	be	considered	surprising,	particularly	given	
the	substantial	overlap	of	antigen	receptor	signalling	pathways	with	T	cells.	Non-redundant	
features	that	distinguish	BCR	from	TCR	signalling	might	also	sensitize	developing	B	cells	to	
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altered	Zn2+	distribution.	 	One	such	distinction	is	the	B	cell-specific	requirement	for	FOXO1	
degradation	in	order	to	suppress	RAG	expression	at	each	positive	selection	checkpoint	19,	40,	
41.	Progression	 through	 these	developmental	 stages	 requires	 the	 sequential	 integration	of	
multiple	 signals,	 determined	 by	 the	 activity	 of	 kinases	 and	 phosphatases.	 Our	 data	 show	
how	these	effects	are	influenced	by	the	intracellular	transport	of	Zn2+	and	how,	in	principle,	
Zn2+	may	modulate	other	outcomes	in	a	variety	of	signalling	contexts.			
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Figure	Legends	
Figure	1.		A	novel	autosomal	recessive	agammaglobulinemia	caused	by	mutations	in	ZIP7.	
(a)	 Pedigrees	 of	 five	 unrelated	 kindreds	 in	which	 subjects	with	 agammaglobulinemia	 and	
absent	 B	 cells	 (P1-P6)	 carry	 the	 indicated	 SLC39A7	 (ZIP7)	 alleles.	 (b)	 Representative	 low	
(scale	bar	40	µm)	and	high-power	(scale	bar	10	µm)	images	of	skin	biopsy	from	patient	P1	
stained	with	hematoxylin	and	eosin,	highlighting	blister	formation	at	the	dermo-epidermal	
junction	 (n=2).	 (c)	 Schematic	 representation	 of	 the	 B	 cell	 precursor	 compartments	within	
the	BM	of	9	age-matched	healthy	donors	(HD),	patients	P1	and	P2	(mutated	ZIP7),	and	12	
disease	controls	with	X-linked	agammaglobulinemia	(XLA),	assessed	by	flow	cytometry.	Pro-
B	 cells	 are	 defined	 as	 CD22+CyCD79a+CyIgM-;	 pre-B	 cells	 are	 CD22+CyCD79a+CD10-
CyIgM+sIgM-	and	immature	B	cells	are	CD22+CD19+CyCD79a+sIgM+sIgD-.	
	
Figure	2.		Multiple	loss-of-function	mutations	in	ZIP7.	(a)	immunoblot	(IB)	of	crude	lysates	
from	dermal	 fibroblasts	 of	 four	healthy	 controls	 and	 two	patients,	 P1	 and	P2,	 probed	 for	
ZIP7	protein	and	GAPDH.	(b)	IB	of	crude	lysates	from	HEK-293T	cells	transfected	individually	
with	FLAG-tagged	WT	(WT)	or	mutant	SLC39A7	alleles,	probed	for	ZIP7	or	DDK	epitopes,	or	
GAPDH.		H191ins	corresponds	to	H199QV	in	mouse.	Images	in	a	and	b	are	representative	of	
3	and	4	independent	experiments,	respectively.	(c)	Immunofluorescence	images	of	HEK293T	
cells	showing	endogenous	ZIP7	(left,	green),	ER	marker	calnexin	(middle,	red)	and	both	ZIP7	
and	calnexin	together	(right,	colocalization	shows	as	orange	signal).	(d)	The	distribution	of	
recombinant	 FLAG-tagged	WT	 (WT)	 or	 indicated	missense	 ZIP7	proteins	 in	HEK293T	 cells,	
transfected	 individually	 and	 probed	 with	 primary	 antibodies	 against	 FLAG	 (green)	 and	
calnexin	(red;	orange	signal	thus	indicates	colocalization	in	the	ER).	Scale	bar,	10µm.	(e)	As	
in	 d,	 but	 recombinant	 truncation	 mutants	 were	 not	 FLAG-tagged	 so	 were	 probed	 with	
primary	anti-ZIP7	antibody.		Images	(c-e)	are	representative	of	3	independent	experiments	
and	Pearson	coefficients	were	uniformly	>0.6.	(f	and	g)	The	location	of	missense	mutations	
within	 the	 predicted	 protein	 structure	 of	 ZIP7,	 modelled	 on	 the	 structure	 of	 Bordetella	
pertussis	ZIP	using	PyMOL;	(f)	en	face	and	(g)	side	view	of	ZIP7.	M1	and	M2	represent	Zn2+	
ions	 bound	 within	 the	 channel,	 TM	 indicates	 transmembrane	 region.	 (h)	 Hypomorphic	
human	 SLC39A7	 alleles	 were	 expressed	 in	 Xenopus	 oocytes	 and	 ZIP7-mediated	 Zn2+	 flux	
revealed	following	exposure	of	Zinquin-loaded	oocytes	to	extracellular	zinc	(see	Methods).	
Normalized	mean	fluorescence	signal	 intensity	 is	shown	with	SD	for	one	experiment,	 (WT,	
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n=3	 oocytes;	 P190A,	 n=4;	 E363K,	 n=3,	 uninjected,	 n=2),	 representative	 of	 4	 independent	
experiments.	 Statistical	 comparison	 was	 by	 one-way	 ANOVA	 with	 Tukey’s	 post-hoc	 test	
(DF=8);	*p=0.0309;	**p=0.0120;	***p=0.0066;	NS,	non-significant.		
	
Figure	3.	Generation	of	an	allelic	series	of	ZIP7	mutant	mice.	(a)	Site-directed	mutagenesis	
of	SLC39A7	 (ZIP7)	 in	mouse	 zygotes	 using	CRISPR/Cas9	 to	 insert	 the	P198A	mutation	 and	
coincidentally	 generate	 an	 allelic	 series	 by	 homologous	 recombination	 (HR)	 and	 non-
homologous	 end	 joining	 (NHEJ),	 here	 showing	 the	 WT,	 Zip7P198A	 (P198A),	 Zip7H199QV	
(H199QV)	 and	 Zip-	 (null)	 alleles.	 (b)	 Total	 B220+	 cell	 population	 as	 percentage	 of	
lymphocytes	 in	 the	BM	of	 25-day-old	mice,	where	 circles	 represent	 individual	mice	 (n=27	
WT,	 6	 H199QV	 Hom;	 13	 P198A/H199QV	 and	 18	 P198A	 Hom);	 data	 are	 pooled	 from	 6	
independent	experiments;	bars	are	mean	and	95%	confidence	intervals	(CI)	and	comparison	
is	by	one-way	ANOVA	(F=51.71;	DF=63)	*=	p<0.0001.	 (c-d)	The	appearance	(c)	and	weight	
(d)	 of	 3-4-week-old	mice	 of	 different	 genotypes,	where	 circles	 in	 (d)	 represent	 individual	
mice	 (n=74	WT,	 14	H199QV	Hom;	 30	 P198A/H199QV	 and	 31	 P198A	Hom);	weights	were	
collected	 over	 time;	 bars	 are	 mean	 and	 95%	 CI,	 and	 comparison	 is	 by	 one-way	 ANOVA	
(F=50.23;	DF=148)*=p<0.0001.	(e)	Phenotypes	associated	with	combinations	of	ZIP7	alleles.	
	
Figure	 4.	 ZIP7	 deficiency	 leads	 to	 a	 B	 cell-intrinsic	 failure	 in	 development.	 (a)	
Representative	flow	cytometry	of	B	cell	development	in	BM	and	spleen	of	WT	and	P198A-
Hom	mice,	gating	on	Hardy	Fractions	(Fr)	A-F	in	the	BM	and	total	B220+CD19+	B	cells	in	the	
spleen.	 (b)	B	cell	 subsets	as	a	percentage	of	 lymphocytes	 in	 the	BM	(two	femurs	and	two	
tibias,	upper	panel)	and	in	the	spleen	(lower	panel),	gating	on	CD19+B220+CD93+IgM+CD23-	
T1,	CD19+B220+CD93+gM+CD23+	T2	and	CD19+B220+CD93+IgMdimCD23+	T3	transitional	B	cells,	
B220+CD19+CD23+CD21dim	follicular	B	cells)	and	B220+CD19+CD23+CD21hi	marginal	zone	(MZ)	
B	 cells.	 	 n=	 6	 mice	 per	 genotype,	 bars	 show	 means	 and	 95%	 CI,	 representative	 of	 5	
independent	experiments.		(c)	Absolute	numbers	of	B	cell	subsets	in	the	BM	(upper	panel)	
and	 spleen	 (lower	 panel)	 from	 lethally	 irradiated	 CD45.1	mice	 reconstituted	 for	 8	 weeks	
with	 CD45.2	WT	 or	 P198A-Hom	 BM	 (gated	 as	 in	 a).	 n=	 5	mice	 per	 genotype,	 bars	 show	
means	 and	 95%	 CI,	 are	 representative	 of	 3	 independent	 experiments.	 	 (d)	 The	 relative	
proportion	of	B	cell	 subsets	 in	BM	(above)	and	spleens	 (below)	of	 lethally	 irradiated	mice	
reconstituted	 for	 8	 weeks	 with	 70:30	 mixtures	 of	 WT	 or	 P198A-Hom	 CD45.2+	 and	 WT	
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CD45.1+	BM	(gated	as	in	a).	Each	bar	represents	one	mouse;	filled	columns	show	percentage	
CD45.2+	cells;	data	are	representative	of	3	experiments.	
	
Figure	5.	ZIP7	deficiency	leads	to	developmental	arrest	at	the	late	pre-B	to	immature	B	cell	
transition.	 (a)	 Heatmap	 showing	 relative	 abundance	 of	 selected	 differentially	 expressed	
transcripts	 in	 sorted	 B	 cells	 from	 Fr	 D	 and	 E	 in	 WT	 and	 P198A-Hom	 mice,	 where	 rows	
represent	individual	mice.	(b)	Median	CD127	expression	on	WT	and	P198A-Hom	B	cells	from	
FrE,	 with	 representative	 histogram	 (left);	 graph	 (right)	 shows	 median	 expression	 in	
individual	mice	(n=5	per	genotype),	bars	are	means	and	95%	CI;	comparison	by	unpaired	t	
test,	 *=p<0.0001	 (representative	 of	 3	 independent	 experiments).	 (c-d)	 BAFFR	 and	 CD20	
staining	in	murine	B	cells	from	FrD	(c)	and	human	pre-B	cells	(d)	comparing	P198A-Hom	and	
WT	 mice	 (representative	 of	 3	 independent	 experiments,	 with	 n=5	 mice	 per	 genotype),	
affected	humans	(P1	and	P2)	and	a	control.		
	
Figure	6.	Reduced	cytoplasmic	zinc	in	the	presence	of	ZIP7	mutation.		(a)	WT	and	P198A-
Hom	 IL-7	dependent	B	 cell	 lines,	 showing	 representative	 flow	cytometry	before	and	after	
stimulation	with	BAFF.	(b)	FLIM	fluorescent	decays	images	of	Zn2+	in	IL-7-dependent	WT	and	
P198A-Hom	B	cells	 transduced	with	 the	cytoplasmic	eCALWY-4	and	eCALWY-6	and	ER	ER-
eCALWY-4	 and	 ER-eCALWY-6	 Zn2+	 reporters.	 Samples	 are	 representative	 of	 cells	with	 the	
mean	 Zn2+	 concentrations	 in	 (c),	 and	 scale	 bar	 5	 µm.	 Relative	 Zn2+	 concentration	
proportional	 to	 a	 color	 scale	 showing	 theoretical	 reporter	 occupancy.	 (c)	 Relative	 Zn2+	
concentration	 in	cytoplasm	and	ER	of	 IL-7	dependent	WT	and	P198A-Hom	cells	expressing	
eCALWY-4	and	eCALWY-6	reporters.	Dots	represent	the	FLIM	fluorescent	decay	in	individual	
B	 cells,	 with	 data	 pooled	 from	 three	 independent	 experiments	 (*=p<0.0001);	 bars	 are	
means	 with	 95%	 CI	 and	 comparison	 by	 t	 Test.	 	 (d-e)	 Super-resolution	 micrographs	 of	
activated	 primary	 human	 B	 cells	 or	 HEK293T	 cells,	 stained	 for	 endogenous	 ZIP7	 (yellow),	
calnexin	 (red)	 and	 surface	 membrane	 (green).	 	 (d)	 Paired	 raw	 and	 deconvolved,	 3D-
rendered	images	are	shown	for	B	cells	(left,	scale	bar	1	µm)	and	HEK293T	cells	(right,	scale	
bar	 5	 µm).	 	 (e)	 Detailed	 view	 of	 indicated	 area	 in	 (d).	 	 (f)	 Violin	 plot	 depicting	minimum	
distance	from	the	centre	of	each	ZIP7+ve	“particle”	to	the	plasma	membrane	of	individual	B	
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(n=8)	 or	 HEK293T	 (n=4)	 cells,	 visualized	 as	 in	 (d-e);	 representative	 of	 2	 independent	
experiments.			
	
Figure	7.	Impaired	ZIP7	function	results	in	reduced	BCR	signalling.		(a)	Representative	flow	
cytometry	analysis	of	BM	from	WT	(upper)	and	P198A-Hom	(lower)	mice,	with	 (right)	and	
without	 (left)	 co-expression	 of	 the	 SWHEL	 heavy	 and	 light	 chain	 transgenes.	 (b)	 Total	
numbers	and	(c)	Mean	fluorescence	intensity	(MFI)	of	surface	IgM,	BAFFR	and	CD20	on	HEL	
binding	cells	from	FrE	in	the	BM	of	lethally	irradiated	CD45.1	mice	reconstituted	for	8	weeks	
with	whole	BM	from	CD45.2	WT	 (open	circles)	or	P198A-Hom	(closed	circles)	SWHEL	mice,	
gated	 on	 B220+CD24+CD21-HEL+IgD-	 cells;	 n=3	 mice	 per	 genotype;	 representative	 of	 6	
independent	 experiments.	 (d)	 Mean	 phospho-specific	 antibody	 binding	 to	 indicated	
intracellular	signalling	molecules	downstream	of	the	BCR,	5	min	after	stimulation	of	whole	
BM	from	WT/	SWHEL	(closed	circles)	and	P198A-Hom/	SWHEL	(open	circles)	mice	with	media	
alone	 or	 10µg/ml	 anti-IgM	 (two	 experiments)	 or	 1,000ng/ml	 soluble	 Hen	 Egg	 Lysozyme	
(sHEL)	and	gated	for	Fr	E	as	in	a.	In	this	figure,	circles	represent	values	from	individual	mice	
(n=3	 per	 genotype),	 bars	 are	means	 of	 groups	 and	 95%	CI;	 representative	 of	 4	 individual	
experiments.		
	
Figure	8.	ZIP7-dependent	inhibition	of	B	cell	phosphatase	activity	(a)	Representative	flow	
cytometric	staining	of	B220+CD43-IgD-	B	cells	from	WT	(upper)	and	P198A-Hom	(lower)	BM,	
showing	phosphatase	activity	 in	 the	pre-	 (IgM-)	 to	 immature	 (IgM+)	B	cell	 transition;	plots	
representative	of	3	separate	experiments,	with	n=4	mice	per	genotype	in	each	experiment.	
(b)	Mean	phosphatase	activity	in	B	cell	Hardy	Fractions	A-F	and	myeloid	cells	(B220-CD43+),	
from	 WT	 (closed	 circles)	 and	 P198A-Hom	 (open	 circles)	 BM.	 Results	 are	 pooled	 from	 3	
independent	 experiments,	 for	 a	 total	 of	 11	mice	per	 group,	with	 comparison	by	 two-way	
ANOVA	 (F	 5.158;	DF	 6);	 *p=0.0438;	 **p=0.0010;	 ***p<0.0001.	 (c)	Mean	 phospho-specific	
antibody	binding	to	indicated	intracellular	signalling	molecules	downstream	of	the	BCR,	30	
min	after	treatment	of	WT	(closed	circles)	and	P198A-Hom	(open	circles)	BM	cells	with	the	
PTEN	 specific	 inhibitor	 BpV(phen),	 in	 the	 absence	 of	 BCR	 stimulation;	 gated	 on	
B220+CD24+CD21-HEL+IgD-	SWHEL	 transgenic	 B	 cells.	 In	 this	 figure,	 circles	 represent	 values	
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from	 individual	mice	 (n=3	per	 genotype),	 bars	 are	means	of	 groups	and	95%	CI.	Data	are	
representative	of	4	independent	experiments.	
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Patient	 P1	 P2	 P3	 P4	 P5	 P6	
ZIP7	variant	1	 P190A	 P190A	 L217P	 E451X	 T395I	 P190A	
ZIP7	variant	2	 E363K	 E363K	 Q372X	 G458A	 T395I	 L217P	
age	(months)		
at	presentation	 <1	 <1	 12	 23	 <1	 26	
IgG	(g/L)	 1.0	 *30.1	 0.14	 *4.58	 <1.4	 <1.7	
IgA	(g/L)	 0.25	 0.16	 <0.06	 <0.06	 **0.17	 <0.07	
IgM	(g/L)	 <0.22	 **0.19	 <0.04	 <0.04	 **0.23	 0.09	
B	cell	(%)	 <0.01	 <0.01	 <0.01	 <0.02	 <0.01	 <0.01	
	
	
Table	1:	Laboratory	parameters	of	humoral	 immunity	 in	6	patients	with	ZIP7	deficiency.		
Quoted	immunoglobulin	(Ig)	values	were	obtained	within	one	month	of	presentation	except	
in	 P3	 (age	 4	 years),	 P4	 (5	 years)	 and	P5	 (2	 years);	 B	 cells	were	measured	 at	 various	 ages	
ranging	from	1	day	(P2)	to	14	years	(P3).	
*	value	obtained	after	Ig	supplementation	
**	declining	to	undetectable	
	
	
	
	
Methods	
	
Study	subjects	and	clinical	immunophenotyping	
Children	 with	 humoral	 immunodeficiency	 and	 absent	 B	 cells	 and	 their	 relatives	 were	
recruited	under	research	protocols	approved	by	 local	ethical	review	(Newcastle	and	North	
Tyneside	 1	 Research	 Ethics	 Committee;	 Institutional	 Review	 Board	 of	 St.	 Jude	 Children's	
Research	 Hospital).	 Peripheral	 blood	 was	 evaluated	 in	 accredited	 clinical	 laboratories	 by	
standard	 methods,	 including	 flow	 cytometric	 immunophenotyping.	 Primary	 dermal	
fibroblast	 cultures	 were	 established	 from	 punch	 skin	 biopsies,	 as	 part	 of	 the	 routine	
diagnostic	workup	of	P1	and	P2,	who	also	underwent	bone	marrow	examination.	 Further	
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clinical	 and	 laboratory	details	are	provided	as	 supplementary	 information	 (Supplementary	
Data	table	1).	
	
Animal	Experiments	
The	 generation	 and	 phenotyping	 of	 the	 ZIP7	 mutant	 mice	 models	 was	 carried	 out	 in	
accordance	with	Animal	[Scientific	Procedures]	Act	1986,	with	procedures	reviewed	by	the	
clinical	 medicine	 animal	 care	 and	 ethical	 review	 body	 (AWERB),	 and	 conducted	 under	
project	licenses	PPL30/2966	and	PPL	P79A4C5BA.	Animals	were	housed	in	specific	pathogen	
free	conditions,	with	 the	only	 reported	positives	on	health	screening	over	 the	entire	 time	
course	 of	 these	 studies	 being	 for	Helicobacter	 hepaticus	 and	 Entamoeba	 spp.	 All	 animals	
were	housed	in	social	groups,	provided	with	food	and	water	ad-libitum	and	maintained	on	a	
12h	 light:12h	 dark	 cycle	 (150–200 lux	 cool	 white	 LED	 light,	 measured	 at	 the	 cage	 floor).	
Phenotyping	experiments	were	not	blinded	or	 randomized	and	no	animals	were	excluded	
from	the	study.	
	
Mice	
A	 CRISPR/Cas9	 nuclease	 was	 designed	 against	 exon	 2	 of	 Slc39a7	 (5’-
GTTACTTACCCAAGGCATGC-3’)	 using	 the	 MIT	 CRISPR	 design	 tool	 (crispr.mit.edu),	 which	
encompassed	 the	murine	 equivalent	 (Proline-198)	 of	 the	 human	Proline-190	 residue.	 The	
target	 site	 protospacer	 was	 cloned	 as	 a	 linker,	 which	 was	 formed	 by	 annealing	 two	
oligonucleotides	 (5’-CACCGTTACTTACCCAAGGCATGC-3‘,	 5‘-
AAACGCATGCCTTGGGTAAGTAAC-3‘)	 into	 a	 sgRNA	 scaffold	 within	 the	 pX330-U6-
Chimeric_BB-CBh-hSpCas9	 plasmid	 (Addgene	 #42230)	 via	 the	 BbsI	 restriction	 site,	
generating	 plasmid	 pX330-ZIP7.	 A	 single	 stranded	 oligonucleotide	 (ssODN)	 (5’-
CACCGCTCTCTGCTCCAGATCCTGCTCAGTTTTGCTTCCGGGGGGCTCCTGGGTGATGCGTTCCTCCA
CCTCATCGCGCATGCATTGGGTAAGTAACTTGTGGGCTCCGCCTCAAAGGCTTAAGCGGTTTTGTTC-
3’)	 harboring	 the	 murine	 equivalent	 of	 the	 desired	 P190A	 (chr6_33169678_C_G)	 point	
mutation,	 together	 with	 a	 silent	 mutation	 used	 to	 mark	 the	 mutated	 allele	 with	 an	NsiI	
restriction	 site,	 was	 used	 as	 a	 template	 for	 homology-directed	 repair.	 The	 activity	 of	 the	
CRISPR/Cas9	 nuclease	 and	 the	 fidelity	 of	 the	 homology-directed	 repair	 were	 verified	 in	
mouse	embryonic	stem	cells	(JM8F6)	electroporated	with	pX330-ZIP7	and	ssODN.	
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For	 the	 generation	 of	 the	 P198A	 knock-in	 mouse	 model,	 C57BL/6J	 (B6)	 zygotes	 were	
microinjected	with	20	ng/μl	of	sgRNA,	10	ng/μl	NLS-Cas9	mRNA	and	20	ng	of	ssODN.	sgRNA	
was	 synthesized	by	 in	 vitro	 transcription	using	 the	MEGAshortscript™	T7	Transcription	Kit	
(ThermoFisher	 Scientific)	 from	 a	 DNA	 template	 to	 add	 a	 5’	 T7	 polymerase	 binding	 site,	
prepared	by	PCR	amplification	of	the	pX330-ZIP7	plasmid.	Capped	mRNA	for	NLS-Cas9	was	
generated	 by	 cloning	 the	NLS-Cas9	 cDNA	 from	 pX330-ZIP7	 into	 pcDNA3.1,	 linearizing	 the	
plasmid	 with	 XhoI	 and	 using	 this	 as	 a	 template	 for	 in	 vitro	 transcription	 using	 the	
mMESSAGE	mMACHINE®	 T7	 Ultra	 Kit	 (ThermoFisher	 Scientific).	 In	 vitro	 transcribed	 RNAs	
were	 purified	 using	 the	 MEGAclear	 Kit	 (ThermoFisher	 Scientific)	 and	 diluted	 prior	 to	
microinjection	in	10	mM	Tris.HCl	pH7.5,	0.1	mM	EDTA	pH	8.0.	Microinjected	zygotes	were	
cultured	overnight	to	the	two-cell	stage	and	surgically	implanted	into	pseudopregnant	CD1	
females.	 Founder	 mice	 harboring	 the	 P198A	 allele	 in	 combination	 with	 putative	 loss-of-
function	 alleles,	 were	 identified	 by	 genotyping	 using	 a	 PCR	 (5’-
GTTCTTAATCGGTGGGAAGCTCC-3’	 and	 5’-CAGCACACCAGTCCCTGGTTTT-3’)	 amplifying	 a	
region	 of	 Slc39a7	 exon	 2,	 followed	 by	 NsiI	 digestion	 to	 detect	 the	 incorporation	 of	 the	
template	 sequence.	 All	 founder	mice	were	 bred	with	WT	 C57BL6/J	mice	 and	 the	 correct	
P198A	allele,	along	with	a	number	of	putative	loss-of-function	indel	alleles,	were	segregated	
in	the	resulting	F1	offspring.	Mice	carrying	the	P198A,	H199QV	and	null	alleles	were	crossed	
to	 pure	 B6	 for	 at	 least	 6	 generations	 (to	 minimize	 the	 risk	 of	 co-segregating	 mutations	
caused	 by	 off	 target	 mutagenesis)	 and	 intercrossed	 to	 generate	 homozygotes	 and	
compound	heterozygotes	of	the	viable	alleles.		
	
BCL2	 (C57BL/6-Tg(BCL2)22Wehi/J),	 swHEL	 (C57BL/6-IghVh10-Brink/J),	 Mb1Cre	
(Cd79b<tm1(cre)Reth),	mice	were	maintained	on	 the	B6	background,	PTEN	 floxed	 (PTENf)	
originated	 from	 the	 129S1/SVimJ	 strain,	 were	 backcrossed	 to	 B6	 for	 at	 least	 three	
generations.	For	BM	chimeras,	CD45.1+	B6	mice	were	 irradiated	with	 two	doses	of	4.5	Gy	
spaced	by	3	hours	and	injected	with	at	least	5x106	BM	cells	of	the	indicated	genotype	(single	
samples	or	30:70	mixture	of	WT	B6.SJL	CD45.1+	BM	and	either	ZIP7P198A	or	WT	B6	(CD45.2+)	
BM).	 Mice	 were	 reconstituted	 for	 8–10	 weeks	 before	 immunization	 or	 analysis.	 All	
experiments	included	age	and	sex-matched	littermate	control	animals.	All	experiments	were	
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approved	by	 the	NIHR	or	 the	Oxford	University	Ethical	Review	Committee	and	performed	
under	UK	Home	Office	Licence.	
	
Zinc	Supplementation	
ZIP7	WT	 and	 P198A	homozygous	 BM	 chimeras	were	 given	water	with	 or	without	 0.5mM	
ZnSO4.7H20	in	drinking	water	for	the	full	period	of	reconstitution	of	8	weeks42.	
	
In	vitro	IgM	stimulation	
Cell	suspensions	from	mouse	BM	were	washed	and	suspended	in	2%	FCS	RPMI.	Cells	were	
warmed	at	37°C	for	5min	and	incubated	at	37°C	(106	cells/well	in	96w	U	bottom	plates)	with	
the	 indicated	 doses	 of	 anti-IgM	 F(ab)2	 (Jackson	 Immunoresearch),	 sHEL	 (Sigma)	 for	 5	
minutes,	 BpV(phen)	 (Sigma)	 for	 30	minutes.	 Subsequent	 surface	 and	 intracellular	 staining	
were	performed	using	the	BD	Cytofix/Cytoperm	protocol.		
	
Flow	Cytometry	
Cell	suspensions	from	mouse	BM	(one	femur	and	tibia),	spleen,	thymus,	mesenteric	lymph	
nodes	and	peritoneal	cavity	were	counted	on	a	hemocytometer	and	stained	in	FACS	buffer	
(DPBS	supplemented	with	2%FCS,	0.05%	Na	Azide,	HEPES	10	mM)	for	30	minutes	on	ice.	
HEL-binding	cells	were	detected	by	incubating	cells	with	200	ng/ml	of	unlabelled	HEL	for	15	
minutes	 on	 ice	 and	 counterstaining	with	HyHEL9	 (a	 gift	 from	 Jason	Cyster)	 conjugated	 to	
Pacific	 Blue.	 Intracellular	 staining	 was	 performed	 using	 the	 Cytofix/Cytoperm	 buffer	 (BD	
Bioscience)	and	 the	antibodies	against	phosphorylated	epitopes.	Data	were	acquired	on	a	
FACSCanto10c	(BD)	and	analyzed	with	FlowJo	Software	(Tree	Star).	
mAbs	against	the	following	mouse	antigens	(clone)	were	purchased	from	Biolegend	unless	
otherwise	 specified:	 B220	 (RA3-6B2)	 AlexaFluor700,	 BV605,	 PE-Cy7,	 PerCP-Cy5.5;	 mouse	
BAFFR	 (7H22-E16)	 PE	 from	 BD;	 BP-1	 PE	 from	 BD;	 CD3	 (17-A2)	 BV421;	 CD4	 (GK1.5)	
		 31	
AlexaFluor700;	 CD8	 (53-6.7)	 Per-CP-Cy5.5;	 CD8	 (53-6.7)	 PerCP-Cy5.5	 and	 PE;	 	 CD11b	
(M1/70)	 APC;	 CD11c	 (N418)	 FITC;	 CD19	 (6D5)	 AlexaFluor700;	 CD20	 (SA275A11)	 APC;	
CD21/35	(7E9)	APC-Cy7;	CD21/35	(7E9)	BV605	from	BD;	CD23	(EBVCS-5)	PE	from	BD;	CD23	
(B3B4)	PE-Cy7;	CD24	(M1/69)	FITC,	AlexaFluor700,	BV605;	CD25	(PC61)	PE	and	BV421;	CD43	
(S7)	 APC	 and	 PerCP-Cy5.5	 from	 BD;	 CD44	 (IM7)	 FITC;	 CD45.1	 (A20)	 PE-Cy7	 and	 APC-Cy7;	
CD45.2	(104)	APC,	BV421	and	BV605;	CD62L	(MEL14)	APC;	CD127	(A7R34)	PE-Cy7	and	APC;	
F4/80	(BM8)	PE-Cy7;	Ly6c	(HK1.4)	PerCP-Cy5.5;	Ly6g	(1A8)	AlexaFluor700;	NK1.1	(PK136)	PE-
Cy7;	 IgM	 (II/41)	 FITC	 from	BD;	 IgM	 (RMM-1)	 BV421;	 IgD	 (11-26c.2a)	 APC-Cy7;	 pAKT-S473	
(M89-61)	APC	from	BD;	pAKT-T308	(J1-223.371)	PE	from	BD;	pBLNK	(J117-1278)	FITC	from	
BD;	pERK	(4B11B69)	FITC;	pPLCg2	(K86-1161)	APC	from	BD;	pSYK	(5F5)	PE;	and	PLCg2	(K86-
1161)	AF647	from	BD.	
mAbs	 against	 the	 following	 human	 antigens	 (clone)	 were	 purchased	 from	 BD	 Bioscience	
unless	otherwise	 specified:	CD10	 (J5)	 FITC	 from	Beckman	Coulter;	CD34	 (8G12)	 FITC;	 sIgD	
(polyclonal)	FITC	from	SBA;	CD36	(CLB-IVC7)	FITC	from	Sanquin;	CD3	(SK7)	FITC	and	PERCP-
Cy5.5;	CD19	(HIB19)	FITC;	CD19	(4G7)	PE;	cyIgM	(polyclonal)	SBA/Agilent	technologies;	TdT	
(HT6)	FITC	from	Agilent;	CD20	(L27)	PE;	sIgM	(polyclonal)	PE	from	ITK/SBA;	CD16	(B73.1)	PE;	
CD56	(C5.9)	PE	from	Zebra/Dako;	CD13	(My7)	PE	from	Beckman	Coulter;	CD33	(P67.6)	PE;	
CD138	 (B-A38)	 PE	 from	Diaclone);	 cyCD79a	 (HM47)	 PE	 from	Beckman	 Coulter;	 CyCD179a	
(VpreB)	(4G7)	PE	from	Beckman	Coulter;	CD33	(P67.6)	PerCP-Cy5.5;	CD16	3G8)	PerCP-Cy5.5;	
CD19	 (SJ5C1)	 PerCP-Cy5.5	 and	 APC;	 CD22	 (S-HCL-1)	 APC;	 CD71	 (LO1.1)	 APC;	 CD38	 (HB7)	
APC;	and	BAFF-R	(11C1)	APC-Cy7	from	Biolegend.	
Alkaline	phosphatase	activity	was	measured	using	 the	cell	permeant	Alkaline	Phosphatase	
Live	Stain	(Thermo	Fisher):	briefly	cells	were	washed	twice	in	serum	free	DMEM	with	MEM	
Vitamins	 (Gibco)	 and	 Na	 pyruvate	 (Sigma),	 incubated	 at	 37°C	 for	 30’	 with	 the	 live	 stain	
diluted	1:500	in	the	same	media;	after	two	washes,	cells	were	stained	on	ice	for	15	minutes	
in	FACS	buffer	and	samples	were	immediately	analyzed	by	flow	cytometry.	
	
Serum	Immunoglobulin	levels	
Total	murine	serum	IgG,	IgM,	IgA	were	measured	using	an	ELISA	quantitation	kit	from	Bethyl	
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Laboratories	and	following	manufacturer	instructions.	
	
Whole	exome	sequencing	
Genomic	DNA	from	P1,	P3,	P4,	P5	and	P6	and	the	parents	of	P3,	P4	and	P6	was	subjected	to	
whole	exome	sequencing.	Exome	capture	was	performed	with	SureSelect	Human	All	Exon	
kits	 (Agilent	 Technologies).	 Paired-end	 sequencing	 was	 carried	 out	 on	 a	 HiSeq	 2500	
sequencing	 system	 (Illumina)	 generating	 100-base	 reads.	 Sequences	 were	 aligned	 to	 the	
GRCh37	 reference	 build	 of	 the	 human	 genome,	 using	 the	 BWA	 aligner43.	 Downstream	
processing	 and	 variant	 calling	 were	 performed	 with	 the	 GenomeAnalysis	 Toolkit44,	
SAMtools45,	 and	 Picard.	 	 Substitution	 and	 InDel	 calls	 were	 made	 with	 the	 GATK	 Unified	
Genotyper.	 All	 variants	 were	 annotated	 with	 an	 annotation	 software	 system	 that	 was	
developed	 in-house14.	 Putative	 disease	 alleles	 were	 validated	 genetically	 by	 Sanger	
sequencing	of	patient	and	family	genomic	DNA.	
	
RNA	sequencing	
Cell	suspensions	from	freshly	isolated	BM	were	obtained	from	straight	chimeras,	5	WT	and	5	
P198A/P198A	mutants,	8	weeks	after	 reconstitution,	and	sorted	using	a	FacsARIA	 III	 (BD),	
using	 the	 following	gating	strategy:	viable,	B220+CD43+CD45.1-CD45.2+CD24+BP1-	 (FrB/pro-
B);	 B220+CD43-CD45.1-CD45.2+IgM-IgD-	 (FrD/late	 preB)	 and	 viable,	 B220+CD43-CD45.1-
CD45.2+IgM+IgD-	(FrE/Immature).	100	cells	per	sample	were	directly	sorted	into	ice	cold	cell	
lysis	buffer	(0.4%	(vol/vol)	Triton	X-100	and	2	U/μl	RNase	inhibitor,	4	x107	dilution	of	ERCC	
spike	in	control,	comprising	a	pre-formulated	blend	of	92	transcripts,	derived	and	traceable	
from	 NIST-certified	 DNA	 plasmids),	 2.5	mM	 dNTPs	 (Thermo-Fisher),	 2.5	 µM	Oligo	 (Oligo-
dT30VN.)	and	immediately	frozen	in	dry	ice.	
	
Sorted	 cells	were	 processed	 using	 the	 Smart-seq2	 protocol	with	minor	 changes46.	 Briefly,	
cDNA	was	quantified	using	the	Agilent	2100	Bioanalyzer	and	tagmentation	was	performed	
using	1	ng	of	pre-amplified	cDNA	and	17	cycles	of	enrichment	PCR.	Indexing	of	the	samples	
was	performed	using	the	Nextera	XT	DNA	Sample	Preparation	Index	kit	 (24	 index	primers,	
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manufacturer	 (Illumina)),	 according	 to	 manufacturer’s	 instructions.	 Following	 library	
preparation,	 the	samples	were	sequenced	on	an	 Illumina	HiSeq	4000	 instrument	as	75	bp	
paired-end	reads.		Bioinformatic	analysis	was	performed	using	in-house	pipelines	and	tools	
(https://github.com/CGATOxford/CGATPipelines)	 and	 47.	Briefly,	 reads	were	aligned	 to	 the	
mm10	mouse	genome	using	hisat2	version	2.1.048,	and	reads	were	quantified	over	feature	
annotations	 (ensemble81)	 using	 featureCounts	 program	 version	 1.4.6	within	 the	 Subread	
software	package49.	 	DESeq2	was	used	for	statistical	analysis	of	the	differential	expression	
for	 each	 gene	 between	WT	 and	 ZIP7P198A/P198A	mice.	 A	 gene	was	 considered	 differentially	
expressed	if	the	log2	fold	change	was	+/-	1	and	significance	value	was	Padj	<	0.05,	which	was	
adjusted	 for	FDR	due	 to	multiple	 testing	procedures	 to	control	 for	 type	 I	error.	Clustering	
and	heat	maps	were	generated	in	R	with	pheatmap	package	version	1.0.8.	For	heat	maps,	
expression	values	were	scaled	per	gene.	
	
Cloning,	expression	and	visualization	of	human	SLC39A7	alleles	
SLC39A7	 cDNA	was	amplified	 from	 total	RNA	extracted	 from	EBV-transformed	B	cells	 and	
cloned	in	pCMV6-AC-myc-DDK	plasmid	between	AscI	and	NotI	(Origene).	Mutagenesis	was	
performed	using	the	Quick	Change	Mutagenesis	kit	(Agilent	Technologies).	Expression	of	WT	
and	 mutant	 isoforms	 was	 assessed	 by	 immunoblotting	 total	 protein	 extracted	(RIPA)	 48	
hours	post-transfection	 (FuGENE®	 HD	 Transfection	 Reagent,	 Promega)	 with	500ng	of	
plasmid	 into	 mycoplasma-free	 HEK293T	 cells.		 Anti-ZIP7	 (HPA053999,	 Sigma	 Aldrich)	
and	anti-Flag	 (F1804,	 Sigma	Aldrich)	antibodies	were	 used	 for	 ZIP7	 detection.	Anti-GAPDH	
(5174,	 Cell	 Signaling)	was	 used	 for	 normalization.	 Alternatively,	 ZIP7	 was	 transfected	
into	HEK293T	cells	 on	 8-well	 chamber	 slide	 (Merck	Millipore	 PEZGS0816)	 pre-coated	with	
Cell-tak	 (Fisher	 Scientific	 10317081).	 Cells	 were	 later	 fixed	 with	4%	 formaldehyde	 in	 PBS	
(28906,	 ThermoFisher	 Scientific),	 permeabilized	 with	0.1%	 Triton-X	 in	 PBS,	 stained	 with	
primary	 anti-ZIP7	 (HPA053999,	 Sigma	 Aldrich)/anti-Flag	 (F7425,	 Sigma	 Aldrich),	 anti-
Calnexin	 (610524B,	 Dbiosciences)	 and	 secondary	goat	 anti-rabbit	 IgG	 Alexa	 Fluor	 594	 (A-
11037,	 ThermoFisher	 Scientific),	 goat	 anti-mouse	 IgG	 Atto	 647N	 (50185,	 Sigma	 Aldrich)	
antibodies,	and	visualized	by	confocal	microscopy	(Leica	TCS	SP8).		
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Primary	 B	 cells	 were	 isolated	 from	 whole	 blood	 donated	 by	 healthy	 individuals	 using	
RosetteSep™	 Human	 B	 Cell	 Enrichment	 Cocktail.	 Purity	 of	 B	 cells	 was	 assessed	 by	 flow	
cytometry,	 and	 found	>80%	 CD19	 staining,	 <1%	 CD3	 staining,	 <4%	 CD14	 staining.	 B	 cells	
were	activated	by	50ng/ml	IL-4	(204-IL,	R&D	Systems),	0.5μg/ml	CD40	ligand	(6420-CL,	R&D	
Systems)	 and	10	μg/ml	 IgM	 (16-5099-85,	 Invitrogen)	 for	 at	 least	 48	hours	 before	 seeding	
onto	8-well	chamber	slides	pre-coated	with	Cell-tak.	Cells	were	fixed	with	4%	formaldehyde	
in	 PBS,	 permeabilized	 with	0.1%	 Triton-X	 in	 PBS,	 stained	 with	 primary	 anti-ZIP7,	 anti-
Calnexin	and	secondary	goat	anti-rabbit	IgG	Alexa	Fluor	594,	and	goat	anti-mouse	IgG	Atto	
647N	or	goat	anti-mouse	IgG	Abberior	STAR	635P	antibodies.	HEK293T	cells	were	stained	by	
the	same	methodology.	 Images	were	acquired	on	a	Leica	TCS	SP8	STED	3X	point	scanning	
confocal	microscope	with	white	 light	 super	 continuum	 lasers	 and	3	 STED	depletion	 lasers	
(592	nm,	660	nm	and	775	nm)	using	STED	WHITE	HC	PL	APO	CS2	100x/1.40	OIL	lens.	 	The	
DAPI	and	AF488	channels	were	acquired	 in	 confocal	mode	while	 the	AF594	and	ATTO647	
channels	were	acquired	in	confocal	and	STED	mode.		
	
Deconvolution,	 colocalization	 analysis	 and	 object	 analysis	 were	 performed	 with	 Huygens	
18.04	from	SVI	(www.svi.nl).	Proximity	measurements	were	performed	using	the	Advanced	
Object	 Analysis	 feature	 in	 Huygens.	 ZIP7	 fluorescence	 signals	 were	 segmented	 into	
individual	objects	and	the	distance	of	their	center	of	mass	to	the	 inner	side	of	the	plasma	
membrane	was	measured.		Violin	plots	were	prepared	in	R.	
	
Primary	Mouse	BM	B	cell	culture,	transduction	and	BAFF	dependent	differentiation	
IL-7-dependent	 BM	 cell	 lines	 were	 cultured	 as	 described50.	 Single	 cell	 suspensions	 were	
isolated	from	the	femur	and	tibia	of	3-4	week	old	mice.	After	RBC	lysis,	cells	were	incubated	
in	DMEM	supplemented	with	10%	FCS	at	37oC,	5%	CO2	for	30	min.	Non-adherent	cells	were	
transferred	to	6-well	plates,	at	750,000	cells/ml,	in	RPMI	supplemented	with	20%	FCS	(R20),	
L-Glutamine,	2-mercapto-ethanol,	non-essential	 amino	acids,	Na	Pyruvate,	MEM	vitamins,	
penicillin/streptomycin,	and	IL-7	10	ng/ml	(Peprotech).	1	x	106	cells	were	transferred	to	each	
well	 of	 a	 6	well	 plate	 in	 a	 final	 volume	of	 4	ml/well.	Half	 the	enriched	RPMI	 volume	was	
replaced	 every	 3	 days.	 	 To	 initiate	 further	 differentiation,	 actively	 proliferating	 cells	were	
then	transferred	to	R20	without	 IL-7	but	containing	BAFF	(Peprotech)	50-100ng/ml	for	3-4	
days,	in	the	presence	or	absence	of	BpV(phen).	
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Primary	B	cell	 transduction	and	Fluorescence	Resonance	Energy	Transfer	–	Fluorescence	
Lifetime	Imaging	microscopy	(FRET-FLIM)	in	live	cells	
On	day	 7	 of	 culture,	 IL-7-dependent	BM	 cells	were	 transduced	with	 Zn2+	 FRET	biosensors	
eCALWY-4	 and/or	 eCALWY-6	 engineered	 with	 Cerulean	 (donor)	 and	 Citrine	 (acceptor)51	
targeted	either	to	the	cytosol	or	the	ER.	ER-eCALWY-4	and	ER-eCALWY-6	are	targeted	to	the	
ER	 by	 an	 N-terminal	 preproinsulin	 sequence	 and	 C-terminal	 Lys-Asp-Glu-Leu	 (KDEL)	
sequence.		For	the	purposes	of	these	experiments,	the	eCALWY	constructs	were	cloned	into	
retroviral	pMX-DEST-puro-derived	vectors.	Filtered	retroviral	supernatants,	harvested	48	hr	
following	 co-transfection	 of	 BOSC23	 cells	 with	 7	 μg	 pCL-Eco	 and	 7	 μg	 pMX-DEST-puro-
derived	 plasmids,	were	 used	 to	 infect	 the	 cell	 cultures	 in	 the	 presence	 of	 polybrene	 (2.5	
µg/ml)	and	HEPES	(20	mM)	by	spinoculation	(850	x	g	for	90	min	at	30°C).	After	a	rest	period	
of	 4	 to	 6	 hours,	 viral	 supernatants	 were	 removed,	 and	 replaced	 with	 IL-7-supplemented	
culture	medium.	Cultures	were	maintained	in	IL-7	media	for	up	to	8-10	days.	
	
Multicolor	images	were	acquired	2-4	days	post-transfection	using	a	Leica	SP8-X-SMD	
confocal	microscope	(Leica	Microsystems)	with	a	63×/1.3	numerical	aperture	water	
immersion	objective.	IL-7-dependent	BM	B	cells	were	allowed	to	adhere	to	poly-L	Lysine	
coated	8	well	ibidi	chamber	slides	in	phenol	red-free	RPMI	immediately	before	imaging.		
Cerulean	and	Citrine	were	excited	at	440	and	514	nm,	respectively,	and	the	fluorescence	
emission	was	detected	using	two	hybrid	detectors	in	photon	counting	mode	at	460-500	and	
520-560	nm,	respectively.	A	third	channel	for	Propidium	Iodide	(PI)	was	also	set	to	evaluate	
cell	death	so	that	only	live	cells	would	be	chosen	for	analysis.	PI	was	detected	using	a	HeNe	
560	nm	laser	and	a	570	–	630	nm	emission	employing	a	third	HyD	detector	and	the	same	
water	immersion	63X	objective.	Only	cells	positive	for	Zn	biosensor	expression	and	negative	
for	PI	(typically	>80%)	were	pre-selected	for	FLIM	acquisition.	FRET	detection	for	eCALWY-4	
and	6	was	based	on	the	time	domain	FLIM	experiments	which	were	performed	using	a	
Time-Correlated	Single	Photon	Counting	(TCSPC)	approach	operated	by	the	FALCON	module	
(Leica	Microsystems,	Mainheim)	integrated	on	the	Leica	SP8-X-SMD	confocal	microscope	
(Leica	Microsystems).	A	440	nm	picosecond	pulsed	diode	laser	PDL	800-B	(PicoQuant)	tuned	
at	40	MHz	was	used	to	excite	the	donor	(Cerulean)	and	the	emitted	photons	passing	
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through	the	460-500nm	emission	filter	and	were	detected	using	the	internal	hybrid	detector	
in	photon	counting	mode.	At	least	1000	photon	events	per	pixel	were	collected	in	all	cases	
(where	each	pixel	=	152	nm	x	152	nm)	and	the	lifetime	analysis	was	carried	out	using	the	
Leica	FALCON	FLIM	integrated	software.	The	acquired	fluorescent	decays	were	fitted	pixel	
by	pixel	binning	the	images	to	4	and	using	a	background	subtraction	of	around	10-20	
photons.	A	bi-exponential	model52	fixing	the	Cerulean	lifetime	to	3.05	ns53	was	employed	to	
recover	the	fraction	of	interacting	donor	fD52,	which	was	then	used	to	recover	the	relative	
concentration	of	Zn2+	(1	–	fD).	
	
Assay	of	ZIP7	activity	in	Xenopus	oocytes	
Xenopus	oocyte	expression:	Xenopus	laevis	frogs	were	purchased	from	the	African	Xenopus	
Facility	(South	Africa).	Care	and	all	experimental	procedures	were	carried	out	in	accordance	
with	 UK	 Home	 Office	 guidelines.	 Oocytes	 were	 prepared	 and	 maintained	 as	 described	
elsewhere54.	SLC39A7	 plasmids	 (see	above)	were	 further	engineered	by	addition	of	 a	RFP	
tag	at	 the	C	 terminus	of	either	WT	or	mutant	ZIP7.	SLC39A7	RNA	was	 transcribed	 in	vitro	
using	the	MegaScript	T7	kit	(Thermo)	and	1	µg	of	Xba	I	linearized	plasmid	DNA	as	a	template.	
10	ng/oocyte	of	RNA	were	injected	and	oocytes	were	incubated	3-5	days	at	18°C	in	Barth’s	
solution.	
	
Zn	 transport	 assay:	Oocytes	were	 incubated	 in	20	µM	Zinquin	 (Enzo	 Life	 Sciences)	 for	30	
min	 followed	 by	 5	 washes	 with	 Barth’s	 solution.	 Zinquin-loaded	 oocytes	 were	 then	
incubated	for	5	min	in	100	µM	ZnCl2	and	visualised	using	an	inverted	Nikon	TiE	microscope	
(excitation	wavelength	380nm,	emission	wavelength	510	nm).	Images	were	captured	at	40x	
using	an	Andor	iXON	DU885	EM-CCD	camera	and	Nikon	Elements	software	(v4.5).	Settings	
were	kept	constant	throughout	each	experiment.	Multiple	images	were	acquired	in	parallel	
focal	planes	starting	at	the	extracellular	matrix	of	the	oocyte	and	scanning	through	to	the	
pigmented	vesicles,	which	 lie	 just	beneath	the	plasma	membrane.	 	After	deconvolution	of	
the	 images	 the	 zinquin	 signal	 was	 visible	 as	 discontinuous	 punctate	 staining	 within	 the	
intervening,	 superficial	 cytoplasm.	 	 To	 quantitate	 this,	 representative	 fields	 of	 50x50	 µM	
were	 specified	 and	 3	 adjacent	 focal	 planes	 (1.2	 µM	 interval)	 were	 analysed	 together	 in	
ImageJ.		To	subtract	background	staining,	ImageJ	was	used	to	specify	the	shape	(size	of	0.2-
		 37	
2	 µM,	 roundness	 0.5-1)	 and	 intensity	 of	 the	 “particles”	 to	 be	 analysed	 and	 a	 composite	
measure	of	signal	strength	was	obtained	as	the	product	of	their	area	and	intensity.		At	least	
3	oocytes	were	analyzed	per	condition	in	each	of	4	experiments.	
	
For	immunoblotting,	1-5	oocytes	were	homogenized	in	10	µl	of	homogenisation	buffer	(1%	
Elugent	 (Calbiochem)	 in	100	mM	NaCl	20	mM	Tris/HCl,	pH	7.6)	per	oocyte.	Samples	were	
centrifuged	at	16000	g	for	3	min	at	RT,	the	supernatant	was	mixed	with	an	equal	volume	of	
SDS	gel	loading	buffer,	and	visualised	by	immunoblotting	as	described55.	
	
ER	stress	assay	
cDNA	 from	 cells	 sorted	 using	 the	 aforementioned	 gating	 strategy	 was	 used	 in	 an	 XBP-1	
splicing	RT-PCR	assay56.	PCR	products	were	run	on	a	2.5%	agarose	gel.	Negative	and	positive	
controls	 were	untreated	 MEFs	 or	 MEFs	 treated	 with	 2	 μg/ml	 tunicamycin	 (Tm)	 for	 4h,	
respectively.	
	
Statistics	
GraphPad	 Prism	 Software	 was	 used	 for	 statistical	 analyses,	 and	 unpaired,	 two	 tailed	
Student’s	 t	 tests	 were	 used	 for	 statistical	 comparison	 between	 groups,	 unless	 otherwise	
specifically	mentioned.		
	
	
Data	availability	statement	
RNA-sequencing	 data	 generated	 for	 this	 study	 (fig	 5,	 supplementary	 figs	 4,5)	 have	 been	
deposited	in	the	Gene	Expression	Omnibus	(GEO)	under	accession	code	GSE108178.		Other	
data	 that	 support	 the	 findings	 of	 this	 study	 (including	 raw	 data	 supporting	 figs	 1	 and	
supplementary	fig	1)	are	available	from	the	corresponding	authors	upon	request.	
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Supplementary Figure 1 
Allele frequency, and predicted severity and evolutionary conservation of mutated residues in SLC39A7. 
(a): Population frequency of putative pathogenic alleles of SLC39A7 (ZIP7) from the GNOMAD database13. (b) Combined Annotation 
Dependent Depletion (CADD)14 scores vs maximum mean allele frequencies of the SLC39A7 variants recorded in this study (red circles) 
and/or GNOMAD Database (blue circles for predicted null mutations (frameshift/stop/essential splicing), green circle (Inframe INDELS 
mutations) or grey circle (missense mutations)). None of the predicted null mutations or Inframe INDELS mutations were found in the 
homozygous state. (c) Alignments of human ZIP7, mouse ZIP7 and Bordetella pertussis ZIP, generated as two pairwise alignments with 
human ZIP7 in BLAST-P, highlighting residues mutated in patients with agammaglobulinemia (missense, yellow; nonsense, pink) and 
predicted transmembrane segments (gray)15. 
 
 
 
Supplementary Figure 2 
Mutant forms of ZIP7 are expressed but display reduced Zn transporter activity. 
(a) Fluorescence micrographs revealing expression of endogenous ZIP7 in primary dermal fibroblasts from healthy control or P1, stained 
with antibody against ZIP7 (red) and DAPI (blue).  Scale bar, 20µm. (b) Impaired Zn2+ conductance of mutant forms of ZIP7 expressed 
in Xenopus oocytes, visualized by zinquin fluorescence.  Left, fluorescence micrographs showing Zn2+-related zinquin signal and right, 
pairwise image analysis in ImageJ, as described in Methods.  Images are representative of 4 independent experiments as exemplified in 
Fig 2h. (c) Western blot of detergent extracts of Xenopus oocytes injected in parallel with those visualized in (b), revealing expression of 
the recombinant ZIP7 proteins. Images are representative of 3 independent experiments. (d-e) Cytoplasmic Zn2+ concentration in HEK-
293T cells stably expressing the genetically encoded cytoplasmic Zn2+ sensor eCALWY-4 and transfected with empty vector (EV), or 
vectors encoding WT, E363K (d) or P190A (e) ZIP7 proteins. Cytoplasmic Zn2+ concentration was calculated by comparing the steady 
state live cell fluorescence intensity with maximum and minimum signals obtained in the presence of TPEN and zinc pyrithione 
respectively, as described in Methods. Total number of cells analyzed was 80 (EV), 55 (WT), 26 (E363K) and 42 (P190A) across 2-4 
experiments. Columns show means and bars the standard error. Comparisons were by one-way ANOVA with Bonferroni’s correction; * 
indicates p=0.0258 and ** p=0.0051. 
 
 
 
Supplementary Figure 3 
Normal T cell development in P198A homozygous mice. 
(a-b) Representative flow cytometry of T cell subsets in the thymus (a) and spleen (b) of WT and P198A-Hom mice. Representative of 3 
independent experiments (c-d) The percentage of B220+ B cells, naïve (CD62L+CD44-), activated (CD62L-CD44+) and memory 
(CD62L+CD44+) CD4+ and CD8+ T cells, NK cells (NK1.1+CD3-), neutrophils (B220-CD3-Ly6g+CD11b+Ly6c+) and monocytes (B220-CD3-
Ly6c++F4/80-) within the leukocyte populations in wild-type (closed circles) and P198A-Hom (open circles) blood (c) and spleen (d). 
Representative of three separate experiments; circles represent individual mice, 5 WT and 5 P198A-Hom; bars means and 95% CI, and 
comparisons by two way ANOVA with Bonferroni’s correction for multiple comparison; *p<0.0001. (e) The relative proportion of thymic or 
splenic CD4+ and CD8+ cells, in lethally irradiated mice reconstituted for 8 weeks with 70:30 mixtures of wild type (WT) or ZIP7P198A/P198A 
(P198A-Hom) CD45.2+ and WT CD45.1+ BM. Filled columns show mean percentage CD45.2+ cells and data are representative of 3 
experiments. 
 
 
 
Supplementary Figure 4 
Transcriptomic analysis of WT and ZIP7 deficient B cells from Hardy Fraction B 
B220+CD43+CD24+BP1- pro-B cells were sorted flow-cytometrically and whole transcriptome analysis performed by RNAseq on 100 cell-
samples from WT and P198A-Hom mutant mice. We identified genes whose transcription varied by at least two-fold between WT and 
P198A-Hom mice with Padj < 0.05 (see Methods). (a-c) Heatmaps show the relative expression level of the subset of these genes that 
are also differentially expressed during normal B cell development: (a) during the transition from Fractions A to B (reduced, purple and 
raised, blue), (b) during the transition from Fractions B to C (reduced, red and raised, green) and (c) between Fractions B and D (reduced, 
yellow and raised, orange), based on the ImmGen database (www.immGen.org). In each heatmap, the far left column indicates the 
direction of change expected from ImmGen; each of the remaining columns represents one mouse and rows individual transcripts. 
 
 
 
 
 
Supplementary Figure 5 
Transcriptomic analysis of WT and P198A-Hom B cells from Hardy Fractions D and E. 
B220+CD43-IgM-IgD- late pre-B (FrD) and B220+CD43-IgM+IgD- immature B cells (FrE) were flow-sorted and whole transcriptome analysis 
performed by RNA-seq on 100 cell-samples from WT and P198A-Hom mice.  We identified genes whose transcription varied by at least 
two-fold between WT and P198A-Hom mice with Padj < 0.05 (see Methods) and filtered these against sets of genes that are also 
differentially expressed at the indicated stages of normal B cell development (www.immGen.org). (a-b) Heatmaps showing the relative 
expression of the subset of genes that show differential expression between wild-type and P198A-Hom B cells in Hardy Fraction D and 
also (a) between Fractions C and D (reduced, yellow and raised, red) and (b) between Fractions D and E (reduced, green and raised, 
blue) of normal mice. (c) Heatmaps showing the relative expression level of the subset of genes that show differential expression between 
wild-type and P198A-Hom B cells in Hardy Fraction E and also between Fractions D and E (reduced, green and raised, blue) of normal 
mice. In each heatmap, the far left column indicates the direction of change expected from ImmGen; each of the remaining columns 
represents one mouse and rows individual transcripts. 
 
 
 
Supplementary Figure 6 
The B cell developmental arrest caused by ZIP7 deficiency is not associated with ER stress and is not corrected by expression 
of the pro-survival factor BCL2. 
(a) RT-PCR assay for the ER-stress-associated shortened Xbp1-splice variant (Xbp1s). Results show RT-PCR of cDNA from WT (lanes 
1-3) or P198A-Hom (lanes 4-6) flow-sorted B cells from FrD and FrE. The controls were tunicamycin treated (Tm) or untreated (Un) 
mouse embryonic fibroblasts (MEFs). Three mice were studied per genotype in the single experiment shown. (b-c) Representative flow 
cytometry analysis of B cell development and maturation in BM (b) and spleen (c) of WT and P198A-Hom mice, with and without co-
expression of a Bcl2 transgene (upper and lower panels).  Gates corresponding to Fr A-F in the BM and total (B220+CD19+), follicular 
(Fo, CD23+CD21+) and Marginal Zone (MZ, CD23-CD21hi) B cells in the spleen are highlighted. (d-e) Absolute numbers of B cells, gated 
as in (b-c), in Hardy Fractions in the BM (d) and in splenic subsets (e) from WT, P198A-Hom, WT BCL2 transgenic (BCL2) and P198A-
Hom BCL2 transgenic (P198A-Hom BCL2) mice, here n=3 per group and representative of 4 independent experiments. Bars show means 
and 95% CI; statistical comparison was by two-way ANOVA with Bonferroni correction for multiple comparison, * =p<0.0001. 
 
 
 
Supplementary Figure 7 
Normal TCR signaling and threshold for activation ZIP7-deficient thymocytes. 
(a-c) Mean phospho-specific antibody binding to indicated intracellular signaling molecules downstream of the TCR, 5 min after 
stimulation of WT (closed circles) and P198A-Hom (open circles) thymocytes with anti-CD3, gated on CD4+CD8+ (a), CD4+ (b) and CD8+ 
cells (c). (d-f) Mean phospho-specific antibody binding to indicated intracellular signaling molecules 30 min after treatment of WT (closed 
circles) and P198A-Hom (open circles) thymocytes with the PTEN specific inhibitor BpV(phen), in the absence of TCR stimulation, gated 
CD4+CD8+ (d), CD4+ (e) and CD8+ cells (f). In this figure, circles represent values from individual mice (n=3 mice per genotype), bars are 
means of groups and 95% CI. Data are representative of 3 independent experiments. 
 
 
 
Supplementary Figure 8 
PTEN contributes to phosphatase activity, but PTEN haploinsufficiency does not rescue B cell development in ZIP7 deficiency; 
normal PLCg2 kinase expression in P198A-Hom cells 
(a) Reduced phosphatase activity in B cells from PTEN-deficient PTENffMb1Cre (n=2) mice compared with wild-type Mb1Cre controls (n=4). 
Plots show gating on the pre-B (Fraction D) population in these animals (left panel) and reduced phosphatase activity thereof in the 
absence of PTEN (middle panel, red fill: PTENffMb1Cre; blue fill: PTENwtMb1Cre); quantification in right panel. Bars show means and 95% 
CI; n=4 PTENwtMb1Cre and 2 PTENf/fMb1Cre mice; experiment done once. (b) Mean anti-PLCg2 antibody staining in wild-type/P198A-
heterozygote (closed circles) and P198A-Hom (open circles) SWHEL immature (B220+CD43-HEL+IgM+IgD-) B cells and B220-CD43- 
controls; bars show means and 95% CI (n=3 mice per group, experiment done once). (c-d) B cell numbers in irradiated CD45.1+ B6 mice 
reconstituted with WT (open triangles), PTENf/+Mb1Cre heterozygote (open circles), P198A-Hom (filled triangles) or P198A-Hom 
PTENf/+Mb1Cre compound mutant BM (filled circles), gated on Hardy Fractions A-F in the BM (c) and total B220+CD19+, follicular 
B220+CD19+CD23+CD21+ and marginal B220+CD19+CD23-CD21++ B cells in the spleen (d). Each symbol represents an individual mouse 
(n= 5 chimeric mice generated per genotype). Bars show means and 95% CI. 
 	
	 
 
Supplementary Table 1 
	
Feature\Patient P1 P2 P3 P4 P5 P6 
ZIP7 variants P190A E363K 
P190A 
E363K 
L217P 
Q372X 
E451X 
G458A 
T395I 
T395I 
P190A 
L217P 
age at presentation (m) <1 < 1 12 23 < 1 26 
age at lymphocyte 
subset analysis (yr) 0.1 0 14 8 3 6 
age at FU (yr) 5.5 3.5 32 16 11 18 
height (cm) [centile] 101.1 [3rd] 85 [3rd] 160 [40th] 152 [5th] 140 [25th] 173 [90th] 
weight (kg) [centile] 16.3 [10th] 13.4 [10th] 60 [50th] 38 [<0.4th] 27 [50th] 71 [73rd] 
bacterial infections yes yes yes yes yes yes 
skin rash blistering dermatitis mild eczematous rash trunk/behind ears 
seborrhoeic 
dermatitis 
with super-
infection 
transient 
necrotising 
granuloma-
tous rash 
other features thrombo-cytopenia 
thrombo-
cytopenia, 
profound 
sensorineural 
deafness 
 
Fe-deficiency 
anaemia 
Vit D 
deficiency 
enteropathy 
transaminitis 
  
parental origin N European N European N European S Asian Hispanic N European 
treatment HSCT HSCT IVIG IVIG IVIG SCIG 
IgG (g/L) 1 30.1§ 0.14 4.58§ <1.4 <1.7 
IgA (g/L) 0.25 0.16* <0.06 <0.06 0.17* <0.07 
IgM (g/L) < 0.22 0.19* <0.04 <0.04 0.23* 0.09 
CD3+ (/ul) 9036 1308 NA 1121 94.5% 6180 
CD4+ T cell (/ul) 8031 1031 NA 566 61.1% 4141 
CD8+ T cell (/ul) 893 268 NA 468 25.4% 2044 
naïve (% of CD4+) 14 48 NA 81 80 NA 
naïve (% of CD8+) 51 183 NA 52 71 NA 
CD4:CD8 ratio 8.99 3.85 NA 1.21 2.4 2 
TCRab(% of CD3+) 98 NA NA 82 93 NA 
HLA-DR+ of CD3+ 34 1 NA NA NA NA 
proliferation to PHA normal normal NA normal NA NA 
NK cell (/ul) 2097 78 NA 215 4.7% 163 
B cell (%) <0.01 <0.01 <0.01 <0.02 <0.01 <0.01 	 *Declining to undetectable; NA, not available; §, on intravenous immunoglobulin (IVIG); HSCT, hematopoietic  
 stem cell transplantation; SCIG, subcutaneous immunoglobulin; FU, follow up; m, month;  PHA, phytohemagglutinin 
